WO2019021510A1 - フラボノイド包接化合物の製造方法 - Google Patents
フラボノイド包接化合物の製造方法 Download PDFInfo
- Publication number
- WO2019021510A1 WO2019021510A1 PCT/JP2018/003177 JP2018003177W WO2019021510A1 WO 2019021510 A1 WO2019021510 A1 WO 2019021510A1 JP 2018003177 W JP2018003177 W JP 2018003177W WO 2019021510 A1 WO2019021510 A1 WO 2019021510A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flavonoid
- cyclodextrin
- glucoside
- isoquercitrin
- composition
- Prior art date
Links
- 150000002215 flavonoids Chemical class 0.000 title claims abstract description 278
- 229930003935 flavonoid Natural products 0.000 title claims abstract description 276
- 235000017173 flavonoids Nutrition 0.000 title claims abstract description 276
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 232
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 178
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 74
- 150000008265 rhamnosides Chemical group 0.000 claims abstract description 58
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 50
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 49
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229930182486 flavonoid glycoside Natural products 0.000 claims abstract description 49
- 150000007955 flavonoid glycosides Chemical class 0.000 claims abstract description 49
- 102000004190 Enzymes Human genes 0.000 claims abstract description 36
- 108090000790 Enzymes Proteins 0.000 claims abstract description 34
- 235000013305 food Nutrition 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 24
- 239000002537 cosmetic Substances 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims description 195
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 claims description 166
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims description 166
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 claims description 166
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims description 137
- 238000006243 chemical reaction Methods 0.000 claims description 114
- 229930182470 glycoside Natural products 0.000 claims description 101
- -1 nariltine Chemical compound 0.000 claims description 81
- 150000002338 glycosides Chemical class 0.000 claims description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 74
- ADSYMQORONDIDD-ZJHVPRRPSA-N hesperetin 7-O-beta-D-glucoside Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC(O)=C2C(=O)C1 ADSYMQORONDIDD-ZJHVPRRPSA-N 0.000 claims description 72
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 64
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 62
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 62
- 235000005493 rutin Nutrition 0.000 claims description 62
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 62
- 229960004555 rutoside Drugs 0.000 claims description 62
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 61
- RXVLWCCRHSJBJV-UHFFFAOYSA-N prunin Natural products OCC1OC(O)C(Oc2cc(O)c3C(=O)CC(Oc3c2)c4ccc(O)cc4)C(O)C1O RXVLWCCRHSJBJV-UHFFFAOYSA-N 0.000 claims description 57
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 50
- 239000001116 FEMA 4028 Substances 0.000 claims description 49
- 229960004853 betadex Drugs 0.000 claims description 49
- 229930182478 glucoside Natural products 0.000 claims description 49
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 47
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 46
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 45
- DLIKSSGEMUFQOK-SFTVRKLSSA-N naringenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C(C(=O)C[C@H](O2)C=3C=CC(O)=CC=3)C2=C1 DLIKSSGEMUFQOK-SFTVRKLSSA-N 0.000 claims description 44
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 41
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 38
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 38
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 36
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 36
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 36
- 229940025878 hesperidin Drugs 0.000 claims description 36
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 32
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims description 21
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims description 21
- 229930019673 naringin Natural products 0.000 claims description 21
- 229940052490 naringin Drugs 0.000 claims description 21
- 238000003379 elimination reaction Methods 0.000 claims description 17
- 108700023372 Glycosyltransferases Proteins 0.000 claims description 14
- 102000051366 Glycosyltransferases Human genes 0.000 claims description 14
- 235000019658 bitter taste Nutrition 0.000 claims description 14
- 230000008030 elimination Effects 0.000 claims description 13
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 13
- 150000001720 carbohydrates Chemical class 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 238000003795 desorption Methods 0.000 claims description 8
- 239000012736 aqueous medium Substances 0.000 claims description 7
- MGYBYJXAXUBTQF-FSFUDZCRSA-N luteolin 7-O-rutinoside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](Oc3cc(O)c4C(=O)C=C(Oc4c3)c5ccc(O)c(O)c5)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@H]1O MGYBYJXAXUBTQF-FSFUDZCRSA-N 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- DCYOADKBABEMIQ-OWMUPTOHSA-N myricitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1=O DCYOADKBABEMIQ-OWMUPTOHSA-N 0.000 claims description 4
- DCYOADKBABEMIQ-FLCVNNLFSA-N myricitrin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1=O DCYOADKBABEMIQ-FLCVNNLFSA-N 0.000 claims description 4
- FKIYLTVJPDLUDL-ZWUNSDNISA-N Apigenin 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(O)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 FKIYLTVJPDLUDL-ZWUNSDNISA-N 0.000 claims description 3
- FKIYLTVJPDLUDL-SLNHTJRHSA-N Isorhoifolin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C=C3C(C(C=C(O3)C=3C=CC(O)=CC=3)=O)=C(O)C=2)O1 FKIYLTVJPDLUDL-SLNHTJRHSA-N 0.000 claims description 3
- FKIYLTVJPDLUDL-FLPYCHHVSA-N Isorhoifolin Natural products C[C@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3cc(O)c4C(=O)C=C(Oc4c3)c5ccc(O)cc5)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H](O)[C@@H]1O FKIYLTVJPDLUDL-FLPYCHHVSA-N 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- ZOQQFMKYEOHRMC-KFOCXKDFSA-N (2r,3r,4r,5r,6s)-2-[[(2r,3s,4s,5r,6s)-6-[5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chromenylium-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-methyloxane-3,4,5-triol;chloride Chemical compound [Cl-].O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=[O+]C3=CC(O)=CC(O)=C3C=2)C=2C=C(O)C(O)=C(O)C=2)O1 ZOQQFMKYEOHRMC-KFOCXKDFSA-N 0.000 claims description 2
- MGYBYJXAXUBTQF-FOBVWLSUSA-N 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C=C3C(C(C=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 MGYBYJXAXUBTQF-FOBVWLSUSA-N 0.000 claims description 2
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 claims description 2
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 claims description 2
- USNPULRDBDVJAO-YRBSALHSSA-O Cyanidin 3-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](Oc2c(-c3cc(O)c(O)cc3)[o+]c3c(c(O)cc(O)c3)c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 USNPULRDBDVJAO-YRBSALHSSA-O 0.000 claims description 2
- HDOMLWFFJSLFBI-UHFFFAOYSA-N Eriocitrin Natural products CC1OC(OCC2OC(Oc3cc(O)c4C(=O)CC(Oc4c3)c5ccc(OC6OC(COC7OC(C)C(O)C(O)C7O)C(O)C(O)C6O)c(O)c5)C(O)C(O)C2O)C(O)C(O)C1O HDOMLWFFJSLFBI-UHFFFAOYSA-N 0.000 claims description 2
- OMQADRGFMLGFJF-MNPJBKLOSA-N Eriodictioside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=C(O)C(O)=CC=2)O1 OMQADRGFMLGFJF-MNPJBKLOSA-N 0.000 claims description 2
- RTATXGUCZHCSNG-TYSPDFDMSA-N Kaempferol-3-O-rutinoside Natural products OC1[C@H](O)[C@@H](O)C(C)O[C@H]1OCC1[C@@H](O)[C@@H](O)C(O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-TYSPDFDMSA-N 0.000 claims description 2
- RTATXGUCZHCSNG-QHWHWDPRSA-N Nicotiflorin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-QHWHWDPRSA-N 0.000 claims description 2
- PLKUTZNSKRWCCA-NQWUONRPSA-O Tulipanin Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(-c3cc(O)c(O)c(O)c3)[o+]c3c(c(O)cc(O)c3)c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 PLKUTZNSKRWCCA-NQWUONRPSA-O 0.000 claims description 2
- RIUBCVFISSKJFL-UHFFFAOYSA-N acacetin 7-rutinoside Natural products CC1OC(OCC2OC(Oc3ccc4C(=O)C=C(Oc4c3)c5ccccc5)C(O)C(O)C2O)C(O)C(O)C1O RIUBCVFISSKJFL-UHFFFAOYSA-N 0.000 claims description 2
- USNPULRDBDVJAO-FXCAAIILSA-O cyanidin 3-O-rutinoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=[O+]C3=CC(O)=CC(O)=C3C=2)C=2C=C(O)C(O)=CC=2)O1 USNPULRDBDVJAO-FXCAAIILSA-O 0.000 claims description 2
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 claims description 2
- 229960004352 diosmin Drugs 0.000 claims description 2
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 claims description 2
- 229960001331 keracyanin Drugs 0.000 claims description 2
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 claims description 2
- RTATXGUCZHCSNG-UHFFFAOYSA-N nicotiflorine Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-UHFFFAOYSA-N 0.000 claims description 2
- MVTFTBIUYLXNKP-UHFFFAOYSA-N scolimoside Natural products COc1cc(O)c2C(=O)C=C(Oc2c1)c3ccc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)c(O)c3 MVTFTBIUYLXNKP-UHFFFAOYSA-N 0.000 claims description 2
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 235000013361 beverage Nutrition 0.000 abstract description 10
- 235000013402 health food Nutrition 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 71
- 239000000047 product Substances 0.000 description 51
- 235000000346 sugar Nutrition 0.000 description 50
- 238000004128 high performance liquid chromatography Methods 0.000 description 37
- 230000000052 comparative effect Effects 0.000 description 33
- 238000001556 precipitation Methods 0.000 description 33
- 238000011156 evaluation Methods 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 239000000796 flavoring agent Substances 0.000 description 31
- 229940088598 enzyme Drugs 0.000 description 30
- 239000002253 acid Substances 0.000 description 25
- 239000000706 filtrate Substances 0.000 description 23
- 235000019634 flavors Nutrition 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 235000019606 astringent taste Nutrition 0.000 description 17
- 238000005259 measurement Methods 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000006866 deterioration Effects 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 12
- 239000012528 membrane Substances 0.000 description 11
- 244000269722 Thea sinensis Species 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- 238000000502 dialysis Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 230000003405 preventing effect Effects 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 9
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 9
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 9
- 235000010209 hesperetin Nutrition 0.000 description 9
- 229960001587 hesperetin Drugs 0.000 description 9
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 9
- 235000019640 taste Nutrition 0.000 description 9
- FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 235000007625 naringenin Nutrition 0.000 description 8
- 229940117954 naringenin Drugs 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 230000001953 sensory effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 235000013616 tea Nutrition 0.000 description 8
- 240000000560 Citrus x paradisi Species 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 235000015110 jellies Nutrition 0.000 description 7
- 239000008274 jelly Substances 0.000 description 7
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 238000005057 refrigeration Methods 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 235000005979 Citrus limon Nutrition 0.000 description 6
- 244000131522 Citrus pyriformis Species 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 6
- 239000004375 Dextrin Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 6
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 235000019425 dextrin Nutrition 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 235000013373 food additive Nutrition 0.000 description 6
- 239000002778 food additive Substances 0.000 description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000005875 quercetin Nutrition 0.000 description 6
- 229960001285 quercetin Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 210000000692 cap cell Anatomy 0.000 description 5
- 239000012295 chemical reaction liquid Substances 0.000 description 5
- 235000013353 coffee beverage Nutrition 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000005562 fading Methods 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 150000008131 glucosides Chemical class 0.000 description 5
- 239000000845 maltitol Substances 0.000 description 5
- 235000010449 maltitol Nutrition 0.000 description 5
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 5
- 229940035436 maltitol Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108010001078 naringinase Proteins 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 0 *c1ccc(C(C2)Oc3cc(*C=*)cc(O)c3C2=O)cc1 Chemical compound *c1ccc(C(C2)Oc3cc(*C=*)cc(O)c3C2=O)cc1 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 108090000637 alpha-Amylases Proteins 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 108010047754 beta-Glucosidase Proteins 0.000 description 3
- 102000006995 beta-Glucosidase Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 229940127554 medical product Drugs 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 235000014214 soft drink Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 244000178937 Brassica oleracea var. capitata Species 0.000 description 2
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 108010084210 citrin Proteins 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000000909 electrodialysis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 238000005858 glycosidation reaction Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 150000002388 hesperetin derivatives Chemical class 0.000 description 2
- 108010030923 hesperidinase Proteins 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 2
- 235000007743 myricetin Nutrition 0.000 description 2
- 229940116852 myricetin Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 150000003244 quercetin derivatives Chemical class 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- FPLMIPQZHHQWHN-UHFFFAOYSA-N tamarixetin Chemical compound C1=C(O)C(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 FPLMIPQZHHQWHN-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000006276 transfer reaction Methods 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PFPQMWRASYNLMZ-LGIMBNBCSA-N 2-(3,4-dihydroxyphenyl)-3-[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 PFPQMWRASYNLMZ-LGIMBNBCSA-N 0.000 description 1
- NLZCOTZRUWYPTP-MIUGBVLSSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLZCOTZRUWYPTP-MIUGBVLSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- WKUHPOMCLBLCOV-MIUGBVLSSA-N Diosmetin 7-O-beta-D-glucopyranoside Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WKUHPOMCLBLCOV-MIUGBVLSSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- MFQIWHVVFBCURA-UHFFFAOYSA-N Floribundoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)CC(C=1C=CC(O)=CC=1)O2 MFQIWHVVFBCURA-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- NRSUOHVIKLCXEE-UHFFFAOYSA-N Isorhamnetin 3-O-beta-D-glucopyranoside Natural products CCC1OC(OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(OC)c4)C(O)C(O)C1O NRSUOHVIKLCXEE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 244000132436 Myrica rubra Species 0.000 description 1
- 235000014631 Myrica rubra Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- KEIZXGINFPDITQ-UHFFFAOYSA-N UNPD138008 Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 KEIZXGINFPDITQ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- XENHPQQLDPAYIJ-PEVLUNPASA-O delphinidin 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC(O)=C(O)C(O)=C1 XENHPQQLDPAYIJ-PEVLUNPASA-O 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000009627 gardenia yellow Substances 0.000 description 1
- 230000036397 gastrointestinal physiology Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- CQLRUIIRRZYHHS-LFXZADKFSA-N isorhamnetin 3-O-beta-D-glucopyranoside Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 CQLRUIIRRZYHHS-LFXZADKFSA-N 0.000 description 1
- UIDGLYUNOUKLBM-GEBJFKNCSA-N isorhamnetin-3-O-rutinoside Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)O2)O)=C1 UIDGLYUNOUKLBM-GEBJFKNCSA-N 0.000 description 1
- 235000014058 juice drink Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000003910 liver physiology Effects 0.000 description 1
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 1
- SUTSVCLKBLJSPQ-UHFFFAOYSA-N luteolin 7-glucoside Natural products OC1C(O)C(O)C(CO)OC1C1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SUTSVCLKBLJSPQ-UHFFFAOYSA-N 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- IEPKWJCBNGNVDF-UHFFFAOYSA-N narcissin Natural products OC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)=C1 IEPKWJCBNGNVDF-UHFFFAOYSA-N 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- HGZHKWZIXPLKLY-UHFFFAOYSA-N tamarixetin 7-beta-D-glucopyranoside Natural products C1=C(O)C(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C=C2O1 HGZHKWZIXPLKLY-UHFFFAOYSA-N 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3481—Organic compounds containing oxygen
- A23L3/3499—Organic compounds containing oxygen with doubly-bound oxygen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/02—Monosaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/12—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/42—Preservation of non-alcoholic beverages
- A23L2/44—Preservation of non-alcoholic beverages by adding preservatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
Definitions
- the present invention relates to a method for producing a flavonoid clathrate compound, a method for producing a flavonoid glycoside composition, a flavonoid clathrate compound, a flavonoid clathrate compound-containing composition, an isoquercitrin glycoside composition, hesperetin-7-glucoside composition
- the present invention relates to a saccharide composition, a naringenin-7-glucoside glycoside composition, a food or a drink containing such a compound or composition, a medical product or a cosmetic product, and a method of improving the solubility of poorly soluble flavonoid having a rhamnoside structure.
- Flavonoids are used for preventing flavor deterioration of food, preventing fading of dyes, etc. because they have antioxidant effect, and Japanese food additives, existing additives, antioxidants list contains flavonoid as an active ingredient
- Japanese food additives, existing additives, antioxidants list contains flavonoid as an active ingredient
- flavonoids have been reported to have anti-tumor, cholesterol reduction, hypotension, hypoglycemia, body fat reduction etc. as physiological action, and they are often used in medicine, food and drink, health food, specified health food, cosmetics and so on. ing.
- Flavonoids are contained in vegetables, fruits, tea, etc. and about 3,000 or more are known, but many of them are poorly water-soluble, therefore, soft drinks, liquids, etc., foods and beverages that require easy water solubility , Difficult to use in medicine and cosmetics.
- solubility of Hesperidin, which is a typical flavonoid, and rutin in water is 0.01% or less, which makes it difficult to use in soft drinks, lotions, and the like.
- the poorly soluble flavonoids can be divided into those with rhamnoside structure and those without rhamnoside structure, but isoquercitrin from which rhamnose is eliminated rather than rutin, hesperidin and naringin with rhamnoside structure, hesperetin-7- It has been reported that glucoside, naringenin and naringenin-7-glucoside are more absorbable in vivo in rats (Non-patent documents 1 to 3).
- the inclusion compound for example, the isoquercitrin (1M) ⁇ ⁇ -cyclodextrin (5M) inclusion compound has a higher internal absorption rate in humans than isoquercitrin, or (Patent Document 1), mouse In the experiment, hesperetin and ⁇ -cyclodextrin inclusion compound etc.
- Non-patent Document 2 naringenin / hydroxypropyl ⁇ -cyclodextrin inclusion compound increases internal absorption (rat) and decreases VLDL (very low lipoprotein) compared to naringenin, and the ratio of glucose clearance And the like have been reported (Non-patent Document 4).
- mice With regard to glucosylation, for example, the antiallergic effects of mice are in the order of “enzyme-treated rutin ⁇ isoquercitrin ⁇ enzyme-treated isoquercitrin” to remove rhamnose, and water-soluble enzyme-treated isoquercitrin is It is reported to show the most effect (non-patent document 5).
- Patent Documents 3 to 6 methods of removing rhamnose from poorly soluble flavonoids having a rhamnoside structure are disclosed in, for example, Patent Documents 3 to 6.
- Patent Documents 2, 7 and 8 disclose.
- Patent Documents 9 and 10 disclose.
- Patent Document 11 discloses a method of solubilizing by combining the poorly soluble flavonoids and soybean saponin and / or malonyl isoflavone glucoside composition in an aqueous medium. It is disclosed.
- An object of the present invention is to newly provide a simple and efficient method for producing a flavonoid clathrate compound and a flavonoid glycoside composition having excellent solubility in water.
- flavonoid clathrates having excellent solubility in water flavonoid clathrate-containing composition, isoquercitrin glucoside composition, hesperetin-7-glucoside glucoside composition, naringenin-7-glucoside glucoside Composition, food or drink containing these compounds or compositions, medical products, or cosmetics, and a method for improving the solubility of poorly soluble flavonoids having a rhamnoside structure.
- a method for producing a flavonoid clathrate compound comprising: an elimination step of treating poorly soluble flavonoid having a rhamnoside structure with an enzyme having rhamnosidase activity in the presence of cyclodextrin to release rhamnose.
- a method for producing a flavonoid glucoside composition comprising a glucosylation step of treating a flavonoid clathrate obtained by the production method according to [1] with a glycosyltransferase to glycosidize the compound.
- a removal step of removing poorly soluble flavonoid having a rhamnoside structure with an enzyme having rhamnosidase activity in the presence of cyclodextrin to release rhamnose, and a flavonoid clathrate obtained by the removal step A method of producing a flavonoid glycoside composition, comprising a glucosylation step of treating glucoside with a glycosyltransferase to form glycosides; [4] A flavonoid clathrate compound in which isoquercitrin is included in ⁇ -cyclodextrin, and the molar ratio ( ⁇ -cyclodextrin / isoquercitrin) of the isoquercitrin to the ⁇ -cyclodextrin is 0.
- the flavonoid inclusion compound which is 9 to 1.8, and the solubility of said isoquercitrin in water is 2% or more;
- the flavonoid inclusion compound which is 9 to 4.0, and the solubility of the isoquercitrin in water is 2.5% or more;
- a flavonoid clathrate compound having a solubility of 0.1% or more of isoquercitrin in water.
- the flavonoid clathrate compound obtained by the production method according to [1] the flavonoid glycoside composition obtained by the production method according to [2] or [3], any one of [4] to [8]
- flavonoid clathrates having excellent solubility in water, flavonoid clathrate-containing composition, isoquercitrin glucoside composition, hesperetin-7-glucoside glucoside composition, naringenin-7-glucoside glucoside It is possible to provide a composition, food and drink including these compounds or compositions, medical products, or cosmetics, and a method of improving the solubility of poorly soluble flavonoid having a rhamnoside structure.
- Example 16 shows an HPLC chromatogram of Example 39.
- 24 shows an HPLC chromatogram of Example 40.
- the present inventors examined the above problems, and by removing the poorly soluble flavonoid having a rhamnoside structure from rhamnose in the presence of cyclodextrin, it is possible to produce a flavonoid inclusion compound simultaneously with rhamnose elimination, It has been found that it can be manufactured more efficiently than the conventional method in which the detachment step and the inclusion step are performed separately. Furthermore, it has surprisingly been found that the flavonoid inclusion compound obtained by such a production method is more excellent in water solubility than the flavonoid inclusion compound produced by the conventional method.
- various cyclic oligosaccharides can be similarly used in addition to cyclodextrin.
- the cyclic oligosaccharide refers to a compound in which monosaccharides are linked cyclically, and more specifically, cyclodextrin, cyclodextran, cyclofructan, cycloartanan, cluster dextrin and the like are exemplified.
- cyclodextrin cyclodextran
- cyclofructan cycloartanan
- cluster dextrin and the like are exemplified.
- an embodiment using cyclodextrin is described as an example, the present invention is not limited thereto, and other cyclic oligosaccharides can be used as well.
- the method for producing a flavonoid clathrate compound of the present invention comprises an elimination step of treating poorly soluble flavonoid having a rhamnoside structure with an enzyme having rhamnosidase activity in the presence of cyclodextrin to release rhamnose.
- the elimination step is a step of removing rhamnose from the poorly soluble flavonoid having a rhamnoside structure to obtain an inclusion compound of flavonoid having no rhamnoside structure and a cyclodextrin (also referred to as "flavonoid inclusion compound").
- the desorption step can be carried out with standing or stirring in a solvent such as water, and air in the head space of the reaction system can be inert gas such as nitrogen to prevent oxidation or browning during the reaction. It is also possible to add an antioxidant such as ascorbic acid to the reaction system.
- the desorption step can be completed by a known method such as a method of inactivating the reaction liquid by heating.
- Examples of poorly soluble flavonoids having a rhamnoside structure include those selected from flavonols, flavanones, flavones and isoflavones, and one or more, preferably two or more hydroxy groups are bonded to the benzene ring of the flavonoid skeleton. And those having a structure retaining rhamnose can be used.
- “sparingly soluble” means that the solubility in water at 25 ° C. is 1.0% by mass or less, preferably 0.1% or less, more preferably 0.01% by mass or less.
- the amount of the slightly soluble flavonoid having a rhamnoside structure is not particularly limited, but it is preferably 0.1 to 20% by mass, more preferably 1 to 15% by mass, still more preferably 2 to 14% in the reaction system. It can be mass%.
- the amount used in the case of using two or more poorly soluble flavonoids having a rhamnoside structure refers to the total amount thereof.
- the raw material containing the poorly soluble flavonoid having a rhamnoside structure to be used in the production method of the present invention does not need to be particularly purified, but is preferably purified.
- the content of the hardly soluble flavonoid having a rhamnoside structure in the raw material is not particularly limited, and is preferably 5% or more, more preferably 20% or more, further preferably 50% or more, and further preferably It is 80% or more, more preferably 90% or more can be used.
- the cyclodextrin (CD) to be present in the elimination step is not particularly limited, but more preferably ⁇ -cyclodextrin ( ⁇ -CD), branched ⁇ -cyclodextrin (branched ⁇ -CD), and ⁇ - One or more selected from the group consisting of cyclodextrin ( ⁇ -CD) can be used.
- Cyclodextrin is a kind of cyclic oligosaccharide having a cyclic structure in which D-glucose is linked by ⁇ -1,4 glycosidic bond, and seven linked ones are linked by eight ⁇ -cyclodextrins. The thing becomes ⁇ -cyclodextrin.
- a branched ⁇ -CD is a ⁇ -CD in which one or more glucose residue, galactosyl group or hydroxypropyl group is linked as a side chain, and is composed of maltosyl ⁇ -CD (G2- ⁇ -CD), hydroxy And propyl- ⁇ -CD (HP- ⁇ -CD).
- G2- ⁇ -CD maltosyl ⁇ -CD
- HP- ⁇ -CD hydroxy And propyl- ⁇ -CD
- the amount of cyclodextrin to be present is not particularly limited, but it is preferably 0.01 to 60% by mass, more preferably 1 to 50% by mass, still more preferably 3 to 40% by mass in the reaction system. be able to. When two or more cyclodextrins are used, the amount refers to the total amount thereof.
- the molar ratio of cyclodextrin (cyclodextrin / flavonoid) to the poorly soluble flavonoid having a rhamnoside structure (cyclodextrin / flavonoid) is preferably 0.01 or more, more preferably 0.1 or more, more preferably from the viewpoint of efficiency. It is 0.9 or more, more preferably 1.0 or more, and from the viewpoint of economy, preferably 10.0 or less, more preferably 6.0 or less, and still more preferably 4.0 or less. And more preferably 3.0 or less.
- the source of the enzyme having rhamnosidase activity is not limited and may be any of animal origin, plant origin, microorganism origin and the like. Furthermore, it may be a recombinant enzyme. Further, the form of the enzyme is not particularly limited.
- enzymes having rhamnosidase activity include hesperidinase, naringinase, ⁇ -glucosidase, pectinase and the like.
- the amount of enzyme having rhamnosidase activity varies depending on the type of enzyme used, reaction conditions, type of poorly soluble flavonoid having rhamnoside structure as a raw material, etc.
- the amount is preferably 0.01 to 1000 U per 1 g of poorly soluble flavonoids having a structure.
- the reaction temperature and the pH of the reaction solution can be selected according to the characteristics of the enzyme used, the reaction conditions are preferably 3 to 7 and more preferably 3.5 to 6.5.
- an enzyme reaction can be performed at pH 7 or less.
- the solvent used in the reaction system includes an aqueous medium.
- the aqueous medium as used herein refers to water or an aqueous solution of an organic solvent. Examples of water include tap water, distilled water, ion-exchanged water, and purified water.
- the organic solvent is not particularly limited as long as it is uniformly mixed with water. As the organic solvent, ethanol is preferable from the viewpoint of being applicable to food.
- the reaction temperature is preferably 10 to 80 ° C., more preferably 40 to 75 ° C.
- the reaction time varies depending on the type of enzyme and the like, but can be, for example, 1 to 100 hours, preferably 2 to 24 hours.
- Enzymes with rhamnosidase activity may have glucosidase activity, and glucosidase activity from poorly soluble flavonoids having rhamnoside structure (hesperidin, rutin, naringin, myricitrin etc.) to aglycone inclusion compounds (quercetin inclusion compound, hesperetin
- aglycone inclusion compounds quercetin inclusion compound, hesperetin
- the flavonoid inclusion compound produced is an inclusion compound of a flavonoid having no rhamnoside structure and a cyclodextrin as described above.
- the inclusion compound refers to a compound which is generated by the inclusion of the other chemical species by the formation of a molecular scale space in which one chemical species conforms in shape and size to the space.
- Flavonoids having no rhamnoside structure include isoquercitrin, quercetin, hesperetin-7-glucoside, hesperetin, naringenin-7-glucoside (purin), naringenin, luteolin-7-glucoside, diosmetin-7-glucoside, myricetin, eriodictio And -7-glucoside, delphinidin-3-glucoside, cyanidin-3-glucoside, isorhamnetin-3-glucoside, kaempferol-3-glucoside, apigenin-7-rutinoside, and acacetin-7-glucoside.
- the molar ratio (cyclodextrin / flavonoid) in the inclusion complex of cyclodextrin to the flavonoid having no rhamnoside structure is preferably 0.01 or more, more preferably 0.1 or more from the viewpoint of efficiency. It is more preferably 0.9 or more, further preferably 1.0 or more, and from the viewpoint of economy, preferably 10.0 or less, more preferably 6.0 or less, and still more preferably It is 4.0 or less, more preferably 3.0 or less.
- the yield of the flavonoid clathrate produced is preferably 10 to 100%, more preferably 40 to 100%, more preferably 70 to 100%, and still more preferably 90 to 100%.
- the yield is the conversion of a poorly soluble flavonoid having a rhamnoside structure to a flavonoid having no rhamnoside structure, and can be calculated by the method described in the examples below.
- the flavonoid clathrate compound produced is a flavonoid having a rhamnoside structure (eg rutin, hesperidin, naringin etc.) which is a raw material, or a flavonoid which may be contained in the raw material (eg, Even in the case of a mixture with quercetin, kaempferol 3-rutinoside, kaempferol 3-glucoside, hesperetin, naringenin etc., the ratio is not limited.
- a rhamnoside structure eg rutin, hesperidin, naringin etc.
- a flavonoid which may be contained in the raw material eg, Even in the case of a mixture with quercetin, kaempferol 3-rutinoside, kaempferol 3-glucoside, hesperetin, naringenin etc., the ratio is not limited.
- the solubility of the flavonoid moiety in water is a difficulty with the rhamnoside structure used Although depending on the type and amount of soluble flavonoid and cyclodextrin, it is preferably 0.01% or more, more preferably 0.015% or more, still more preferably 0.02% or more, and still more preferably 1 It is not less than 0%, more preferably not less than 2.0%, still more preferably not less than 2.5%, still more preferably not less than 3%.
- the upper limit is not particularly limited, but can be, for example, 20% or less.
- the solubility in water of the flavonoid moiety is a mass percent concentration at 25 ° C. and can be measured by the method described in the examples below.
- the solubility of said isoquercitrin in water is preferably from 0.9 to 4.0, more preferably from 0.9 to 1.8. It is 0.01% or more, more preferably 2% or more, further preferably 2.5% or more, and still more preferably 3% or more.
- a flavonoid clathrate compound in which hesperetin-7-glucoside is included in cyclodextrin wherein the molar ratio of the hesperetin-7-glucoside and the inclusion complex of the cyclodextrin (cyclodextrin / hesperetin-7-glucoside) When it is 1.0 to 3.0, the solubility of the hesperetin-7-glucoside in water is preferably 0.01% or more, more preferably 0.02% or more, and still more preferably It is 0.03% or more.
- a composition comprising a flavonoid clathrate compound and rhamnose, which is unrefined, can be obtained.
- the molar ratio (rhamnose / flavonoid) of the flavonoid in the flavonoid clathrate compound to the eliminated rhamnose is 0.8 to 1.2.
- the method for producing a flavonoid clathrate compound of the present invention when the above-mentioned yield is not 100%, it contains a poorly soluble flavonoid having a rhamnoside structure as an unreacted material.
- the molar ratio of the flavonoid in the flavonoid clathrate compound to the hardly soluble flavonoid in the flavonoid clathrate-containing composition containing such an unreacted substance (the sparingly soluble flavonoid / flavonoid in the clathrate) is stable over a long period of time From the viewpoint of the property, it is preferably 0.1 or less, more preferably 0.08 or less, and still more preferably 0.05 or less.
- the lower limit value is not particularly limited, but may be 0.001 or more, 0.003 or more, 0.004 or more, 0.01 or more.
- the flavonoid inclusion compound obtained by the production method of the present invention can improve the solubility of the sparingly soluble flavonoid having a rhamnoside structure. More specifically, the molar ratio of the poorly soluble flavonoid having a rhamnoside structure and the flavonoid inclusion compound obtained by the production method of the present invention, the flavonoid in the above flavonoid inclusion compound and the hardly soluble flavonoid Mixed in the medium so that the flavonoid / slightly soluble flavonoid) in the clathrate is preferably 0.1 to 0.9, more preferably 0.1 to 0.7, still more preferably 0.1 to 0.3 By doing this, the solubility of the poorly soluble flavonoid having a rhamnoside structure can be improved.
- the medium refers to an aqueous medium or an aqueous solution containing food or Chinese medicine such as saccharides, salts, acidulants, sweeteners, flavors, glycerin, propylene glycol, etc., food additives, lemon extract, Chinese herbal extract, etc. It says inside.
- This solubility improvement method may be carried out by using the flavonoid clathrate-containing composition containing the unreacted substance as it is, or by adding the flavonoid clathrate compound to the poorly soluble flavonoid having the rhamnoside structure. You may implement.
- the sparingly soluble flavonoid having a rhamnoside structure and the flavonoid inclusion compound obtained by the production method of the present invention are as described above, for example, rutin and isoquercitrin- ⁇ -cyclodextrin inclusion compound, and hesperidin Hesperetin-7-glucoside- ⁇ -cyclodextrin inclusion compound, naringin and naliginin-7-glucoside- ⁇ -cyclodextrin inclusion compound, rutin and naligenin-7-glucoside- ⁇ -cyclodextrin inclusion compound may be combined It can be mentioned.
- the resin treatment step adsorption method, ion exchange method, etc.
- the membrane treatment step Ultrafiltration membrane treatment, reverse osmosis membrane treatment, zeta potential membrane treatment, etc.
- the flavonoid clathrate-containing composition obtained in the desorption step is adsorbed with a porous synthetic adsorbent, washed with water to remove rhamnose and the like, then alcohol-eluted and purified by spray drying.
- Rhamnose or the like can be fractionated and used in the food field, medicine, quasi-drug field, and cosmetic field, etc.
- only flavonoids can be purified from the produced flavonoid clathrates.
- the dilution material is not particularly limited as long as it does not impair the effects of the present invention, and, for example, sugars such as sugar, glucose, dextrin, starches, trehalose, lactose, maltose, starch syrup, liquid sugar, etc .; ethanol, propylene glycol And alcohols such as glycerin; sorbitol, mannitol, xylitol, erythritol, maltitol, sugar alcohols such as reduced starch syrup, mannitol and the like; or water.
- the additive include phosphates, organic acids, assistants such as chelating agents, and antioxidants such as ascorbic acid.
- the process for producing a flavonoid glycoside composition of the present invention comprises a glycoside forming step of treating a flavonoid inclusion compound obtained by the method for producing a flavonoid inclusion compound of the present invention with a glycosyltransferase to glucosify it.
- a poorly soluble flavonoid having a rhamnoside structure is treated with an enzyme having rhamnosidase activity in the presence of cyclodextrin to remove rhamnose, and a flavonoid clathrate compound obtained by the removal step It comprises a glucosylation step of treating with glycosyltransferase to glucosify.
- the flavonoid clathrates obtained through the elimination step and the elimination step are as described above.
- the term “obtained through the elimination step” is not intended to exclude those including steps other than the elimination step, but also includes those obtained through an optional purification step or the like.
- the glycoside forming step is a step of causing the flavonoid clathrate compound obtained through the elimination step to act as a glycosyltransferase by acting a glycosyltransferase to obtain a flavonoid glycoside composition. Further, the glycoside forming step can be carried out in the presence of a solvent such as water or stirring as in the desorption step, and the head of the reaction system is prevented to prevent oxidation or browning during the reaction. Space air may be replaced with an inert gas such as nitrogen, or it may be possible to add an antioxidant such as ascorbic acid to the reaction system.
- the glycosidation step can be completed by a known method such as a method of inactivating the reaction liquid by heating.
- the cyclodextrin of the flavonoid inclusion compound becomes a sugar donor, and the flavonoid glycoside composition can be produced, but there is no limitation on the additional provision of the sugar donor.
- Specific examples of the additionally donated sugar donor include starch, dextrin, partially hydrolyzed starch, such as maltooligosaccharide, xylooligosaccharide, and substances containing these.
- the glycosyltransferase is not particularly limited as long as it is an enzyme having a glycosyl transfer activity to the flavonoid clathrate compound obtained through the elimination step.
- the glycosyltransferase is not limited in its source, and all of animal origin, plant origin, microorganism origin and the like can be used. Furthermore, artificial enzymes by genetic engineering, partial hydrolysis and the like may be used.
- the form of the glycosyltransferase is not particularly limited, and a dried product of the enzyme protein, an enzyme immobilized with an insoluble carrier, a liquid containing the enzyme protein, and the like can be used.
- glycosyltransferases include cyclodextrin glucanotransferase, glucosyltransferase, ⁇ -glucosidase, ⁇ -glucosidase, ⁇ -galactosidase, ⁇ -galactosidase, ⁇ -amylase, xylanase, pullulanase, arabinofuranosidase etc. .
- glycosyltransferase used varies depending on the type of enzyme used, conditions of glycosyltransferase, species of sugar, etc. For example, in the case of cyclodextrin glucanotransferase, 1 to 10000 U is preferable per 1 g of the flavonoid inclusion compound.
- cyclodextrin glucanotransferase 1 to 10000 U is preferable per 1 g of the flavonoid inclusion compound.
- glycosidation of poorly soluble flavonoids in order to solubilize the poorly soluble flavonoids, it is general to carry out an enzyme reaction on the alkali side, but in the alkaline range above pH 7, the flavonoids become less stable and degraded -In addition to being easily browned, a brown matter removal step is required, and a desalting step by alkali neutralization is also needed.
- the flavonoid clathrate compound obtained by the production method of the present invention is solubilized at a high concentration even when the poorly soluble flavonoid is at pH 7 or less, so that the enzyme reaction is efficiently glycosylated at pH 7 or less. Therefore, from the viewpoint of production efficiency and quality, the pH is preferably 3 to 7, and more preferably 6 to 6.8. However, it is also possible to carry out sugar transfer in an alkaline region or to adjust the pH to 7 or less after adjusting to an alkaline region.
- the solvent used in the reaction system includes an aqueous medium.
- the reaction temperature is preferably 40 to 70 ° C., more preferably 50 to 65 ° C.
- the reaction time varies depending on the type of enzyme and the like, but can be, for example, 0.5 to 120 hours, preferably 1 to 30 hours.
- the binding mode of the sugar linked to the flavonoid may be either ⁇ -linked or ⁇ -linked.
- the type of sugar to be bound is not particularly limited, but is preferably at least one selected from 5 to 6 monosaccharides such as glucose, galactose and fructose.
- the number of sugars attached is preferably 1 to 30, more preferably 1 to 25, still more preferably 1 to 20, still more preferably 1 to 15, and further preferably It is 1 to 10 pieces.
- the flavonoid glycoside composition is a composition containing a mixture of glycosides in which the above saccharides are bound to flavonoid, and there is no limitation on the proportion of each glycoside bound, but from the viewpoint of not impairing the flavor of food and drink etc. The following modes are preferable.
- the content of glycosides of 4 or more is 30 mol% or more and 50 mol% or less.
- Glc means a glucose residue and n means an integer of 0 or 1 or more
- n The content of glycosides of 4 or more is 30 mol% or more and 50 mol% or less.
- Glc means a glucose residue and n means an integer of 0 or 1 or more
- Glc means a glucose residue and n means an integer of 0 or 1 or more
- the number of bonds (n number) of glucose groups can be adjusted arbitrarily.
- the flavonoid glycoside composition can be obtained by treating the various flavonoid glycoside compositions after formation with various amylases ( ⁇ -amylase, ⁇ -amylase, glucoamylase, ⁇ -glucosidase, etc.) singly or in combination.
- the number of glucose sugar chains in the molecule can be reduced to obtain a flavonoid glycoside composition having any glucose sugar chain length.
- the method for producing the flavonoid glycoside composition of the present invention is not particularly limited to the purification as necessary other than the desorption step and the glycoside formation step, and the resin treatment step (adsorption method, ion exchange ), Membrane treatment process (ultrafiltration membrane treatment method, reverse osmosis membrane treatment method, zeta potential membrane treatment method etc), and purification by electrodialysis method, salting out, acid precipitation, recrystallization, solvent fractionation method etc. can do.
- the flavonoid glycoside composition obtained in the glycoside forming step is adsorbed to the glycoside composition with a porous synthetic adsorbent, washed with water, eluted with alcohol, and then spray dried to obtain a powder. You can get it.
- dilution material are the same as those described in the method for producing a flavonoid clathrate compound.
- the solubility in water in the flavonoid glycoside composition obtained by the production method of the present invention is preferably 0.01% or more, more preferably 0.015% or more, and more preferably 0.01% or more, in terms of flavonoid value. It is 0.02% or more, more preferably 0.1% or more, and still more preferably 0.5% or more.
- the upper limit is not particularly limited, but can be, for example, 20% or less.
- the flavonoid clathrate compound and the flavonoid glycoside composition obtained by the production method of the present invention are a slightly soluble flavonoid having a rhamnoside structure which is said to be slowly absorbed in the body, or a flavonoid glycoside composition having a rhamnoside structure In combination with the above, it can be in the form of a food in which the absorption rate in the body is continuously improved.
- a combination of isoquercitrin inclusion compound and rutin for example, a combination of isoquercitrin glucoside composition and a rutin glucoside composition (for example, ⁇ G rutin, Toyo Shokuhin Co., Ltd.), hesperetin-7-glucoside package And a hesperidin glucoside composition (for example, monoglucosyl hesperidin, for example), a combination of a clathrate compound and a hesperidin glycoside composition (for example, ⁇ G hesperidin, Toyo Seikan Co., Ltd.), a hesperetin-7-glucoside glycoside composition and a hesperidin glycoside composition Hayashibara) and the like.
- a hesperidin glucoside composition for example, monoglucosyl hesperidin, for example
- a combination of a clathrate compound and a hesperidin glycoside composition for example,
- the flavonoid glycoside composition obtained by the manufacturing method of this invention can improve the solubility of another poorly soluble flavonoid by combining with another hardly soluble flavonoid.
- the molar ratio (glycoside composition / other sparingly soluble flavonoid) is preferably 0.1 to 0.5, more preferably 0.1 to 0.3, and still more preferably 0.1. It is ⁇ 0.15.
- the flavonoid clathrate compound and / or the flavonoid glycoside composition obtained by the production method of the present invention is excellent not only in the absorptivity as described above but also in the prevention of discoloration, the prevention of flavor deterioration and the storage stability. It can be suitably used as a food composition, a pharmaceutical composition, a cosmetic composition, and a composition for food additives.
- As a material for fat accumulation suppression, endurance improvement, anti-fatigue, cold disease improvement, skin condition improvement, hair growth, muscle atrophy suppression, sleep, and also as food additive antioxidant, anti-fading agent, flavor deterioration inhibitor It can be used.
- Food additive compositions include sweeteners, colorants, preservatives, thickening stabilizers, color formers, bleaches, fungicides, gum bases, bitter agents, brighteners, sour agents, seasonings, emulsifiers, enhancers, It can be added for manufacturing agent, for prevention of deterioration of perfume, etc., and can be made into a mixed preparation. That is, in the present invention, it is possible to provide a food / beverage product, a medicine, a cosmetic, etc. containing the flavonoid clathrate compound and / or the flavonoid glycoside composition obtained by the production method of the present invention.
- Food and drink include food and beverage, for example, dietary supplement, health food, food for specified health, functional indication food, food for diet, integrated health food, supplement, tea drink, coffee drink, juice And soft drinks and drinks.
- the pharmaceutical preparation includes pharmaceuticals or quasi-drugs, and is preferably an oral preparation or an external preparation for skin, and is a solution, a tablet, a granule, a pill, a syrup, or a lotion, a spray, an ointment It can be in the form of an agent.
- Cosmetics may be in the form of cream, liquid lotion, milky lotion, or spray.
- the content of the flavonoid clathrate compound and / or the flavonoid glycoside composition in the food, drink, medicine or cosmetic of the present invention is not particularly limited, but the solubility is preferably based on the preferable daily intake of flavonoids.
- the design can be made as appropriate in consideration of the preference and the like.
- the blending amount of the flavonoid clathrate compound and / or the flavonoid glycoside composition obtained by the production method of the present invention in a food composition as the flavonoid portion is preferably 0.001 to 30% by mass, more preferably May be 0.01 to 20% by mass, more preferably 0.02 to 10% by mass, and the flavonoid inclusion compound and / or the flavonoid glycoside composition is preferably 10 mg to 20 g per day, more preferably
- the compounding amount in the food composition can also be determined so that 30 mg to 10 g, more preferably 100 mg to 5 g can be ingested once to several times (for example, three times).
- the blending amount of the flavonoid clathrate compound and / or the flavonoid glycoside composition to the food additive preparation is preferably 0.001 to 50% by mass, more preferably 0.01 as a volume at which the flavonoid exhibits an effect. It can be used at ⁇ 40 wt%, more preferably 0.1 to 30 wt%.
- Flavonoid Inclusion Compound-Containing Composition Examples 1 to 31 In a beaker of 1000 ml volume, poorly soluble flavonoid (rutin or hesperidin) having a rhamnoside structure (rutin or hesperidin) and cyclodextrin were added as shown in Tables 1 and 2, water was added to 1000 g, and adjusted to 70 ° C., pH 4.5. After that, 3 to 30 g of naringinase (Amano Enzyme Ltd.
- Comparative Examples 1 to 3 The compositions of Comparative Examples 1 and 3 were prepared in the same manner as in Examples 16 and 17 except that cyclodextrin was not added. Further, the composition of Comparative Example 2 was prepared in the same manner as in Example 16 except that dextrin was added instead of cyclodextrin.
- Comparative example 101 To a 100 ml volume of beaker, add isoquercitrin and ⁇ -cyclodextrin prepared below as shown in Table 1-2, add water to make 100 g, and stir at 70 ° C, pH 4.5 for 24 hours Thereafter, the temperature was returned to room temperature, and filter paper filtration was performed to prepare a composition containing an inclusion compound of isoquercitrin and ⁇ -cyclodextrin.
- isoquercitrin 10 g of rutin used in Table 1 was added to a 100 L aqueous solution, and adjusted to 70 ° C., pH 4.5. After that, 1 g of naringinase (Amano Enzyme (155) / g) was added while stirring, and recovered and dried to obtain 7.2 g of isoquercitrin having a content of 96% or more. It was confirmed by HPLC using the reagent isoquercitrin (Wako) that it is identical.
- Examples 101 to 109 A composition containing an inclusion compound of naringenin-7-glucoside and ⁇ -cyclodextrin was prepared in the same manner as in Examples 1 to 31 except that the raw materials shown in Table 2-2 were used.
- Comparative example 102 The composition of Comparative Example 102 was prepared in the same manner as Example 104 except that cyclodextrin was not added.
- RTN 50 kg of buds of Enju, which is a rutin leguminous plant prepared below, was immersed in 500 L of hot water for 3 hours, and then the filtrate was separated by filtration to obtain a filtrate. Thereafter, the mixture was cooled to room temperature, and the precipitated component was separated by filtration, and the precipitated portion was washed with water, recrystallized, and dried to obtain 3190 g of rutin having a content of 96% or more. The same peak was confirmed by HPLC using the reagent rutin (Wako).
- HSP Hesperidin (content 97% or more, manufactured by Hamari Chemical Co., Ltd.)
- NRG naringin (content: more than 95% manufactured by SIGMA)
- ⁇ -CD ⁇ -cyclodextrin (manufactured by Pearl Ace)
- ⁇ -CD ⁇ -cyclodextrin (manufactured by Pearl Ace)
- Dextrin Sandeck # 70 (manufactured by Sanwa Starch Co., Ltd.)
- Isoquercitrin was confirmed by the same peak by HPLC using the reagent isoquercitrin (Wako).
- the conversion in each of Examples 1 to 16 was 96% or more.
- the conversion rate in Comparative Example 1 in which the amount of enzyme was the same as in Example 16 was 56%, and the conversion rate in Comparative Example 2 was as low as 57%.
- conversion (%) peak area of naringenin-7-glucoside ⁇ 100 / (peak area of naringin + peak area of naringenin-7-glucoside). Naringenin-7-glucoside was confirmed by HPLC using the reagent naringenin-7-glucoside (Wako) by the same peak. The conversion of Examples 101 to 109 and Comparative Example 102 was 95% or more.
- Hesperetin-7-glucoside (HPT-7G) concentration (absorbance method) The reaction completed solutions of Examples 17 to 31 and Comparative Example 3 were allowed to stand at room temperature, and then 1 ml of supernatant was filtered and used as a measurement sample.
- Naringenin-7-Gelcoside (NGN-7G) concentration (absorbance analysis method) After leaving the reaction completed solutions of Examples 101 to 109 and Comparative Example 102 at room temperature, 1 ml of the supernatant was filtered and used as a measurement sample.
- HPLC (SHIMADZU) analysis ⁇ HPLC conditions: Column: Inertsil NH 2 (4.6 ⁇ 150 mm (GL Sciences), eluent: 65% acetonitrile / water (v / v), detection: Suggested refractometer RID-10A (SHIMADZU), From the flow rate: 1 ml / min, column temperature: 40 ° C>, after preparing calibration curves of ⁇ -cyclodextrin (Wako) and ⁇ -cyclodextrin (Wako), calculate the molar concentration of cyclodextrin in the sample, and The molar ratio of cyclodextrin / isoquercitrin, cyclodextrin / hesperetin-7-glucoside, cyclodextrin / naringenin-7-glucoside was calculated from the molar concentration of citrin, hesperetin-7-glucoside, and na
- Solubility IQC solubility, HPT-7G solubility, NGN-7G solubility
- the reaction completed solutions of Examples 1 to 31 and 101 to 109 and Comparative Examples 1 to 3 and 101 and 102 were allowed to stand at room temperature, then filtered through filter paper and lyophilized to obtain a dried product.
- the dried product prepared above was added to a 100 ml beaker containing 50 ml of water at 50 ° C. with stirring until it was completely dissolved and precipitated. After standing at room temperature (25.degree.
- Inclusion ratio of isoquercitrin-cyclodextrin inclusion compound (isoquercitrin concentration in the inclusion compound (concentration of filtrate at room temperature after completion of reaction) ⁇ 100 / reaction complete solution (unfiltered mixed solution) The concentration of isoquercitrin in) was almost 100%.
- the clathration ratio (clathrate compound in the suspension state from beginning to end only by mixing and heating isoquercitrin and ⁇ -cyclodextrin in the same composition as Example 10
- concentration of isoquercitrin concentration of filtrate after standing at room temperature after reaction
- concentration of isoquercitrin in end solution unfiltered mixed solution
- Hessperetin-7-glucoside concentration in the clathrate compound concentration of filtrate after standing at room temperature
- the filtrate at room temperature was dissolved, and the clathrate ratio to be a naringenin-7-glucoside-cyclodextrin inclusion compound (naringenin-7-glucoside in the clathrate compound)
- concentration (concentration of filtrate at room temperature after completion of the reaction) ⁇ 100 / naringenin-7-glucoside concentration of the reaction completed solution (unfiltered mixed solution) was about 100%.
- the obtained dried product was used as a commercially available carbonated beverage (sugar-free) ("Natural Alps natural water sparkling", manufactured by Suntory Ltd.), coffee beverage (non-sugar) ("Wanda Gold Black”, manufactured by Asahi Beverage Co., Ltd.), and tea 0.1 mass% of isoquercitrin conversion concentration was added to (“Oi Ocha”, manufactured by Ito En Co., Ltd.), and sensory evaluation (different taste, sweetness) was performed by five panelists, with no additive added as a control. Each average point was calculated according to the following evaluation criteria. The results are shown in Table 3.
- Sweetness evaluation criteria 1 Sweetness feels strongly 2: Sweetness feels somewhat strong 3: Sweetness feels 4: I feel sweetness faintly 5: I do not feel sweetness
- the molar ratio ( ⁇ CD / IQC) is 1.0 to 1.8
- the taste and sweetness are small compared to the molar ratio of 2.0 to 4.0
- the beverage is Etc. from the viewpoint of reducing the influence on food flavor such as
- the molar ratio is 2.0 to 3 when the molar ratio (CD / HPT-7G) is 1.0 to 1.9.
- the off-tastes flavors different from no added
- sweetness can be suitably used for food and drink.
- Flavonoid Glycoside Composition Examples 32-39 A small amount of alkali is added to the reaction solution (70 ° C., pH 4.5, isoquercitrin concentration 2.3% by mass) prepared in Example 4 to adjust to pH 6.5, 60 ° C., and then cyclodextrin glucanotransferase ( CGTase: 20 g of Amano Enzyme Co., Ltd. (trade name "Contizyme", 600 U / ml) was added to start the reaction, and kept for 24 hours.
- CGTase 20 g of Amano Enzyme Co., Ltd. (trade name "Contizyme", 600 U / ml) was added to start the reaction, and kept for 24 hours.
- the resulting reaction solution was heat-killed, filtered and then freeze-dried to obtain 158 g (sample 1) of an isoquercitrin glycoside composition containing a compound represented by the general formula (1).
- the solubility to water in the obtained isoquercitrin glycoside composition (sample 1) was 2.7% in terms of isoquercitrin.
- the obtained isoquercitrin glucoside composition (sample 1) is dissolved in water and then passed through a column filled with Diaion HP-20 (porous synthetic adsorption resin, manufactured by Mitsubishi Chemical Corporation) to distribute isoquercitrin.
- the saccharide composition such as rhamnose was removed by adsorbing the saccharide composition and washing with water twice as much as the resin volume. Thereafter, the eluate obtained by eluting the adsorbed component with twice the resin volume, 65% (v / v) ethanol, was concentrated and then freeze-dried to prepare a glycoside composition of Example 39.
- the HPLC chromatogram of Example 39 is shown in FIG. This result was equivalent to the HPLC chromatogram of sample 1.
- the isoquercitrin glycoside composition (sample 1) was adsorbed and washed with water in the same manner as in Example 39, and eluted with 10 to 60% (v / v) ethanol concentration to be eluted.
- Glc means a glucose residue and n means an integer of 0 or 1 or more
- Examples 40 to 46 A small amount of alkali is added to the reaction solution (70 ° C., pH 4.5, hesperetin-7-glucoside concentration 2.9 mass%) prepared in Example 22 to adjust to pH 6.5 and 60 ° C., and then cyclodextrin glucano is prepared.
- the reaction was initiated by adding 5 g of a transferase (CGTase: Amano Enzyme Co., Ltd., trade name "Contizyme", 600 U / ml) and maintained for 24 hours.
- CCTase Amano Enzyme Co., Ltd., trade name "Contizyme", 600 U / ml
- the resulting reaction solution was heat-killed, filtered and spray-dried to obtain 136 g of hesperetin-7-glucoside glucoside composition (sample 2) containing the compound represented by the general formula (2).
- the solubility in water of the obtained hesperetin-7-glucoside glycoside composition (sample 2) was 5.1% in terms of hesperetin-7-glucoside.
- the obtained hesperetin-7-glucoside glucoside composition (sample 2) is dissolved in water, and then passed through a column filled with Diaion HP-20 (porous synthetic adsorption resin, manufactured by Mitsubishi Chemical Corporation) to obtain hesperetin-
- the 7-glucoside glucoside composition was adsorbed and washed with water twice the resin volume to remove saccharides such as rhamnose. Thereafter, the eluate from which the adsorption component was eluted with 65% (v / v) ethanol of twice the resin volume was concentrated and then lyophilized to prepare the glycoside composition of Example 40.
- the HPLC chromatogram of Example 40 is shown in FIG. This result was equivalent to the HPLC chromatogram of sample 2.
- hesperetin-7-glucoside glycoside composition (sample 2) was adsorbed, washed with water, and eluted with an ethanol concentration of 10 to 60% (v / v) in the same manner as in Example 40. . Solutions obtained by combining the eluates (10, 20, 30, 40, 50, 60% (v / v) eluates) and adjusting the molar ratio were concentrated and then lyophilized to give the glycosides of Examples 41 to 46. The composition was prepared. The solubility of the glycoside composition of Examples 40 to 46 in water was 10% or more in terms of hesperetin-7-glucoside.
- Glc means a glucose residue and n means an integer of 0 or 1 or more
- Solubility (IQC conversion value, HPT-7G conversion value)
- the solubilities of the flavonoid glycoside compositions of Samples 1 and 2 and Examples 32 to 46 were calculated the isoquercitrin concentration and the hesperetin-7-glucoside concentration in the same manner as the IQC solubility and HPT-7G solubility, The isoquercitrin conversion value and the hesperetin-7-glucoside conversion value were used.
- the thing in which precipitation is not observed when each conversion value is 10% or more described solubility as 10% or more.
- Astringent taste evaluation criteria 1 Strongly feel astringent taste 2: Slightly strong astringent taste 3: Slightly astringent taste 4: Slightly astringent taste 5: No astringent taste
- the bitter taste, the bitter taste and the astringent taste are significantly reduced, and can be suitably used in food and drink applications. Since all of the glycoside compositions of Examples 32 to 46 are excellent in solubility, they can be suitably used for applications unrelated to taste, for example, applications such as cosmetics.
- sensory evaluation at a naringenin-7-glucoside conversion concentration of 0.05% significantly reduced the bitter taste, the bitter taste, and the astringent taste.
- Molar ratio in flavonoid glycoside composition (rhamnose / flavonoid) From the molar concentration and isoquercitrin equivalent value calculated after the measurement of rhamnose content of sample 1 and sample 2 (under the same conditions as HPLC sugar analysis method, preparing a calibration curve with rhamnose (Wako)), from hesperetin-7-glucoside value
- the molar ratio to the calculated molar concentration (rhamnose / flavonoid) was 0.8 to 1.2.
- the flavonoid clathrate-containing composition of Example 16 and the flavonoid glycoside composition of Example 39 were added to an acid sugar solution (pH 3.0) containing 0.05% of a red cabbage pigment preparation. It was added so that the concentration in terms of citrin was 0.005%, and the dye residual rate after 4 hours of UV fade meter processing was compared, and a fading preventing effect was observed as compared with the non-added product. The results are shown in Table 5.
- Example 40 Each dried product obtained and the flavonoid glycoside composition of Example 40 are added to an additive-free grapefruit jelly so that hesperetin-7-glucoside concentration becomes 0.005%, and an additive grapefruit jelly is added. Were prepared respectively. Thereafter, the temperature is raised to 93 ° C., these are sealed in a transparent glass bottle, cooled and stored for one month in a room under normal fluorescent light at room temperature, according to the following evaluation criteria When it compared by, the flavor degradation inhibitory effect was observed by each additive. The results are shown in Table 7.
- Acid sugar solution prescription (mass%) 1. Sugar 10 2. Citric acid (crystal) 0.08 3. Trisodium citrate pH adjustment (pH 3) 4. Water remaining
- the amount of quercetin derivative in the collected serum sample is the method of Makino et al. (Biol. Pharm. Bull. 32 (12) 2034, 2009), the amount of hesperetin derivative is the method of Yamada et al. (Biosci. Biotechnol. Biochem, 70 (6) High Performance Liquid Chromatography (SHIMADZU) and analysis using a photodiode array detector (SPD-M30A, SHIMADZU) according to the method described in U.S. Pat. The results are shown in Tables 10 and 11.
- Table 10 shows the concentrations ( ⁇ M) of quercetin and quercetin derivatives (isorhamnetin, tamarixetin) and the total area under the blood concentration time curve (AUC) ( ⁇ M ⁇ h) for 0 to 3 hours. Further, since no hesperetin derivative was detected in Table 11, the hesperetin concentration ( ⁇ M) from 0 to 3 hours and the area under the blood concentration time curve (AUC) ( ⁇ M ⁇ h) were shown.
- Example 39 isoquercitrin glycoside composition of Example 39, 100 ⁇ mol / kg (in terms of IQC), is almost the same as the internal absorption rate of Example 16, and Hesperetin of Example 40
- IQC / RTN refers to the area ratio (peak of isoquercitrin) after HPLC (SHIMADZU, conversion same conditions) analysis using 1 ml of acid sugar solution immediately after dissolving the preparation component as a measurement sample Area / peak area of rutin) is shown as a molar ratio.
- Comparative examples 107 to 110 A solution was prepared in the same manner as in Comparative Examples 103 to 106 except that the component doses shown in Table 15 were used, and sensory evaluation was performed on astringent taste immediately after cooling. Moreover, the thing of the same component dose was prepared separately, and after refrigeration storage (4 degreeC, 12 months), the presence or absence of the precipitation was visually observed. The results are shown in Table 15.
- RTN / IQC refers to the area ratio (peak area of rutin) after analysis by HPLC (SHIMADZU, conversion rate same conditions) using 1 ml of acid sugar solution immediately after dissolving the preparation components as a measurement sample.
- the peak area of isoquercitrin is shown as a molar ratio.
- the composition containing the inclusion compound of isoquercitrin and ⁇ -cyclodextrin obtained by the production method of the present invention, containing rutin in a specific amount provides long-term stability of the inclusion compound It confirmed that there was no problem in sex. In addition, it was confirmed that the astringent taste was weak, and the influence on the flavor when added to food and drink was reduced. The astringency was particularly weak in the RTN / IQC (molar ratio) range of 0.08 or less (Examples 114 to 117).
- RTN Heat-dissolvable product of 10 g of 99.5% ethanol by volume of 90 g and rutin (preparation: isoquercitrin / rutin molar ratio is 0.3 / 99.7)
- IQC-rCD lyophilized product of Example 16 ( Rhamnose removed by dialysis, (rutin / isoquercitrin molar ratio is 0.3 / 99.7))
- IQC Heated product of 18 g of 99.5% ethanol and 2 g of isoquercitrin (preparation: rutin / isoquercitrin molar ratio is 0.3 / 99.7)
- Flavonoid clathrate-containing composition, and formulation example of flavonoid glycoside composition Formulation Example 1: Grapefruit drink
- the isoquercitrin- ⁇ -cyclodextrin clathrate-containing composition of Example 16 is dried.
- the beverage containing the substance was prepared.
- the product can be suitably used as a beverage.
- Formulation Example 2 Jelly A jelly containing the dried product of the hesperetin-7-glucoside / ⁇ -cyclodextrin inclusion compound-containing composition of Example 22 was prepared for preventing flavor deterioration.
- the product can be suitably used as a food (jelly).
- composition of Example 40 was prepared for the purpose of improving the dullness and swelling of the skin.
- the product can be suitably used as a skin care cosmetic.
- Formulation Example 4 Tablet A tablet containing the dried product of the hesperetin-7-glucoside / ⁇ -cyclodextrin inclusion compound-containing composition of Example 22 was prepared for temperature relaxation.
- the product can be suitably used as a health food.
- Coffee Beverage A coffee beverage containing the dried product of the isoquercitrin glucoside composition of Example 39 was prepared to reduce body fat.
- the product can be suitably used as a food for specified health use.
- Example 6 Black Tea Beverage A black tea beverage containing the dried product of the hesperetin-7-glucoside glucoside composition of Example 40 was prepared to reduce neutral fat. The product can be suitably used as a functional indicator food.
- Formulation Example 7 Hair growth agent A hair growth agent containing a dried product of the hesperetin-7-glucoside / ⁇ -cyclodextrin inclusion compound-containing composition of Example 22 was prepared for scalp improvement.
- Formulation Example 8 Hair Shampoo A hair shampoo containing a dried product of the hesperetin-7-glucoside ⁇ ⁇ -cyclodextrin inclusion compound-containing composition of Example 27 was prepared for the purpose of preventing inflammation.
- Formulation Example 9 Dietary Tablet A tablet containing the dried product of the naringenin-7-glucoside- ⁇ -cyclodextrin inclusion compound-containing composition of Example 109 was prepared for a diet. This product can be used favorably as a health food.
- flavonoid clathrates and flavonoid glycoside compositions having excellent solubility in water can be efficiently produced, and pharmaceuticals, foods and drinks, health foods, foods for specified health use, and It can be suitably used in the field of cosmetics and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Description
[1]ラムノシド構造をもつ難溶性フラボノイドを、シクロデキストリンの存在下、ラムノシダーゼ活性を有する酵素で処理してラムノースを脱離する脱離工程を含む、フラボノイド包接化合物の製造方法、
[2][1]記載の製造方法により得られたフラボノイド包接化合物を糖転移酵素で処理して配糖体化する配糖体化工程を含む、フラボノイド配糖体組成物の製造方法、
[3]ラムノシド構造をもつ難溶性フラボノイドを、シクロデキストリンの存在下、ラムノシダーゼ活性を有する酵素で処理してラムノースを脱離する脱離工程、及び前記脱離工程を経て得られたフラボノイド包接化合物を糖転移酵素で処理して配糖体化する配糖体化工程を含む、フラボノイド配糖体組成物の製造方法、
[4]イソクエルシトリンがγ-シクロデキストリンに包接されたフラボノイド包接化合物であって、前記イソクエルシトリンと前記γ-シクロデキストリンとのモル比(γ-シクロデキストリン/イソクエルシトリン)が0.9~1.8であり、前記イソクエルシトリンの水への溶解度が2%以上である、フラボノイド包接化合物、
[5]イソクエルシトリンがγ-シクロデキストリンに包接されたフラボノイド包接化合物であって、前記イソクエルシトリンと前記γ-シクロデキストリンとのモル比(γ-シクロデキストリン/イソクエルシトリン)が0.9~4.0であり、前記イソクエルシトリンの水への溶解度が2.5%以上である、フラボノイド包接化合物、
[6]イソクエルシトリンがβ-シクロデキストリンに包接されたフラボノイド包接化合物であって、前記イソクエルシトリンと前記β-シクロデキストリンとのモル比(β-シクロデキストリン/イソクエルシトリン)が1.0~3.0であり、前記イソクエルシトリンの水への溶解度が0.1%以上である、フラボノイド包接化合物、
[7]ヘスペレチン-7-グルコシドがシクロデキストリンに包接されたフラボノイド包接化合物であって、前記ヘスペレチン-7-グルコシドと前記シクロデキストリンとのモル比(シクロデキストリン/ヘスペレチン-7-グルコシド)が1.0~3.0であり、前記ヘスペレチン-7-グルコシドの水への溶解度が0.01%以上である、フラボノイド包接化合物、
[8]ナリンゲニン-7-グルコシドがβ-シクロデキストリンに包接されたフラボノイド包接化合物であって、前記ナリンゲニン-7-グルコシドと前記β-シクロデキストリンとのモル比(β-シクロデキストリン/ナリンゲニン-7-グルコシド)が1.0~3.0であり、前記ナリンゲニン-7-グルコシドの水への溶解度が0.01%以上である、フラボノイド包接化合物、
[9][4]~[8]いずれか記載のフラボノイド包接化合物とラムノースとを含み、前記フラボノイド包接化合物と前記ラムノースとのモル比(ラムノース/フラボノイド包接化合物)が0.8~1.2である、フラボノイド包接化合物含有組成物、
[10][4]~[8]いずれか記載のフラボノイド包接化合物と、ラムノシド構造をもつ難溶性フラボノイドとを含み、前記フラボノイド包接化合物中のフラボノイドと前記難溶性フラボノイドとのモル比(難溶性フラボノイド/包接化合物中のフラボノイド)が0.001~0.1である、フラボノイド包接化合物含有組成物、
[11]下記一般式(1)で示される化合物を含むイソクエルシトリン配糖体組成物であって、前記配糖体組成物中、n=0の配糖体の含有量が10モル%以上30モル%以下であり、n=1~3の配糖体の含有量が50モル%以下であり、n=4以上の配糖体の含有量が30モル%以上である、イソクエルシトリン配糖体組成物、
[12]下記一般式(2)で示される化合物を含むヘスペレチン-7-グルコシド配糖体組成物であって、前記配糖体組成物中、n=0の配糖体の含有量が10モル%以上30モル%以下であり、n=1~3の配糖体の含有量が50モル%以下であり、n=4以上の配糖体の含有量が30モル%以上である、ヘスペレチン-7-グルコシド配糖体組成物、
[13]
下記一般式(3)で示される化合物を含むナリンゲニン-7-グルコシド配糖体組成物であって、前記配糖体組成物中、n=0の配糖体の含有量が10モル%以上30モル%以下であり、n=1~3の配糖体の含有量が50モル%以下であり、n=4以上の配糖体の含有量が30モル%以上である、ナリンゲニン-7-グルコシド配糖体組成物、
[14][1]記載の製造方法により得られたフラボノイド包接化合物、[2]又は[3]記載の製造方法により得られたフラボノイド配糖体組成物、[4]~[8]いずれか記載のフラボノイド包接化合物、[9]又は[10]記載のフラボノイド包接化合物含有組成物、[11]記載のイソクエルシトリン配糖体組成物、[12]記載のヘスペレチン-7-グルコシド配糖体組成物、及び[13]記載のナリンゲニン-7-グルコシド配糖体組成物からなる群より選択される1種以上の化合物又は組成物を含む、飲食品、
[15][1]記載の製造方法により得られたフラボノイド包接化合物、[2]又は[3]記載の製造方法により得られたフラボノイド配糖体組成物、[4]~[8]いずれか記載のフラボノイド包接化合物、[9]又は[10]記載のフラボノイド包接化合物含有組成物、[11]記載のイソクエルシトリン配糖体組成物、[12]記載のヘスペレチン-7-グルコシド配糖体組成物、及び[13]記載のナリンゲニン-7-グルコシド配糖体組成物からなる群より選択される1種以上の化合物又は組成物を含む、医薬品、
[16][1]記載の製造方法により得られたフラボノイド包接化合物、[2]又は[3]記載の製造方法により得られたフラボノイド配糖体組成物、[4]~[8]いずれか記載のフラボノイド包接化合物、[9]又は[10]記載のフラボノイド包接化合物含有組成物、[11]記載のイソクエルシトリン配糖体組成物、[12]記載のヘスペレチン-7-グルコシド配糖体組成物、及び[13]記載のナリンゲニン-7-グルコシド配糖体組成物からなる群より選択される1種以上の化合物又は組成物を含む、化粧品、並びに
[17]ラムノシド構造をもつ難溶性フラボノイドと、[1]記載の製造方法により得られたフラボノイド包接化合物あるいは[4]~[8]いずれか記載のフラボノイド包接化合物とを、前記フラボノイド包接化合物中のフラボノイドと前記難溶性フラボノイドとのモル比(包接化合物中のフラボノイド/難溶性フラボノイド)が0.1~0.9となるように媒体中で混合する、ラムノシド構造をもつ難溶性フラボノイドの溶解性を向上させる方法に関する。
イソクエルシトリンがγ-シクロデキストリンに包接されたフラボノイド包接化合物であって、前記イソクエルシトリンと前記γ-シクロデキストリンとの包接体でのモル比(γ-シクロデキストリン/イソクエルシトリン)が、生産コストを抑える観点から、好ましくは0.9~4.0である場合、より好ましくは0.9~1.8である場合には、前記イソクエルシトリンの水への溶解度が好ましくは0.01%以上であり、より好ましくは2%以上であり、さらに好ましくは2.5%以上であり、さらに好ましくは3%以上である。
イソクエルシトリンがβ-シクロデキストリンに包接されたフラボノイド包接化合物であって、前記イソクエルシトリンと前記β-シクロデキストリンとの包接体でのモル比(β-シクロデキストリン/イソクエルシトリン)が1.0~3.0である場合には、前記イソクエルシトリンの水への溶解度が好ましくは0.01%以上であり、より好ましくは0.02%以上であり、さらに好ましくは0.03%以上であり、さらに好ましくは0.05%以上である。
ヘスペレチン-7-グルコシドがシクロデキストリンに包接されたフラボノイド包接化合物であって、前記ヘスペレチン-7-グルコシドと前記シクロデキストリンとの包接体でのモル比(シクロデキストリン/ヘスペレチン-7-グルコシド)が1.0~3.0である場合には、前記ヘスペレチン-7-グルコシドの水への溶解度が好ましくは0.01%以上であり、より好ましくは0.02%以上であり、さらに好ましくは0.03%以上である。
ナリンゲニン-7-グルコシドがβ-シクロデキストリンに包接されたフラボノイド包接化合物であって、前記ナリンゲニン-7-グルコシドと前記β-シクロデキストリンとの包接体でのモル比(シクロデキストリン/ナリンゲニン-7-グルコシド)が1.0~3.0である場合には、前記ナリンゲニン-7-グルコシドの水への溶解度が好ましくは0.01%以上であり、より好ましくは0.02%以上であり、さらに好ましくは0.03%以上である。
下記一般式(1)で示される化合物を含むイソクエルシトリン配糖体組成物であって、前記配糖体組成物中、n=0の配糖体の含有量が10モル%以上30モル%以下であり、n=1~3の配糖体の含有量が50モル%以下であり、n=4以上の配糖体の含有量が30モル%以上である、イソクエルシトリン配糖体組成物。好ましくは、n=0の配糖体の含有量が10モル%以上30モル%以下であり、n=1~3の配糖体の含有量が35モル%以上45モル%以下であり、n=4以上の配糖体の含有量が30モル%以上50モル%以下である。
下記一般式(2)で示される化合物を含むヘスペレチン-7-グルコシド配糖体組成物であって、前記配糖体組成物中、n=0の配糖体の含有量が10モル%以上30モル%以下であり、n=1~3の配糖体の含有量が50モル%以下であり、n=4以上の配糖体の含有量が30モル%以上である、ヘスペレチン-7-グルコシド配糖体組成物。好ましくは、n=0の配糖体の含有量が10モル%以上25モル%以下であり、n=1~3の配糖体の含有量が35モル%以上50モル%以下であり、n=4以上の配糖体の含有量が30モル%以上50モル%以下である。
下記一般式(3)で示される化合物を含むナリンゲニン-7-グルコシド配糖体組成物であって、前記配糖体組成物中、n=0の配糖体の含有量が10モル%以上30モル%以下であり、n=1~3の配糖体の含有量が50モル%以下であり、n=4以上の配糖体の含有量が30モル%以上である、ナリンゲニン-7-グルコシド配糖体組成物。
実施例1~31
1000m1容量のビーカーに、ラムノシド構造をもつ難溶性フラボノイド(ルチン又はヘスペリジン)とシクロデキストリンを表1、2に示すように添加し、水を加えて1000gにし、70℃、pH4.5に調整した。その後撹拌しながら、ナリンギナーゼ(天野エンザイム(株)155u/g)を3~30g添加し、24時間反応させた後、室温に戻して、ろ紙濾過後、ラムノシド構造をもたないフラボノイド(イソクエルシトリン又はヘスペレチン-7-グルコシド)とシクロデキストリンとの包接化合物、及び脱離したラムノースを含むフラボノイド包接化合物含有組成物を得た。
シクロデキストリンを添加しない以外は実施例16、17と同様にしてそれぞれ比較例1、3の組成物を調製した。また、シクロデキストリンに代えて、デキストリンを添加した以外は実施例16と同様にして比較例2の組成物を調製した。
100m1容量のビ-カ-に、下記で調製したイソクエルシトリンとγ-シクロデキストリンを表1-2に示すように添加し、水を加えて100gとし、70℃、pH4.5で24時間攪拌後、室温に戻して、ろ紙濾過し、イソクエルシトリンとγ-シクロデキストリンとの包接化合物を含有する組成物を調製した。
表1で使用したルチン10gを100L水溶液に添加し、70℃、pH4.5に調整した。その後撹拌しながら、ナリンギナーゼ(天野エンザイム(株)155u/g)を1g添加し、回収・乾燥することで、含量96%以上のイソクエルシトリンを7.2g得た。試薬イソクエルシトリン(Wako)を用いてHPLCにて同一であることを確認した。
表2-2に示す原料を使用した以外は実施例1~31と同様にしてナリンゲニン-7-グルコシドとβ-シクロデキストリンとの包接化合物を含有する組成物を調製した。
シクロデキストリンを添加しない以外は実施例104と同様にして比較例102の組成物を調製した。
RTN:下記で調製したルチン
マメ科植物であるエンジュのつぼみ50kgを500Lの熱水に3時間浸漬した後、濾別した濾液を取得した。その後、室温まで冷却して沈殿した成分を濾別し、沈殿部を水洗、再結晶、及び乾燥することにより、含量96%以上のルチン3190gを得た。試薬ルチン(Wako)を用いてHPLCにて同一ピークであることを確認した。
HSP:ヘスペリジン(含量97%以上、浜理薬品工業株式会社製)
NRG:ナリンジン(含量95%以上 SIGMA社製)
β-CD:β-シクロデキストリン(パールエース社製)
γ-CD:γ-シクロデキストリン(パールエース社製)
デキストリン:サンデック#70(三和澱粉工業株式会社製)
実施例1~16、及び比較例1~2の未濾過の反応終了混合液を測定サンプルとし、HPLC(SHIMADZU)の面積比(イソクエルシトリンのピーク面積/ルチンのピーク面積)<HPLC条件;カラム:CAPCELL PAK C18 SIZE 4.6mm×250mm(SHISEIDO)、溶離液:20%(v/v)アセトニトリル/0.1%リン酸水溶液、検出:351nm、流速:0.4ml/min、カラム温度:70℃>より、転化率(%)=イソクエルシトリンのピ-ク面積×100/(ルチンのピ-ク面積+イソクエルシトリンのピ-ク面積)として算出した。イソクエルシトリンは、試薬イソクエルシトリン(Wako)を用いてHPLCにて同一のピークであることで確認した。実施例1~16における転化率はいずれも96%以上であった。一方、実施例16と同酵素量で比較した比較例1における転化率は56%、比較例2における転化率は57%と低いものであった。
実施例17~31、及び比較例3の未濾過の反応終了混合液を測定サンプルとし、HPLC(SHIMADZU)の面積比(ヘスペレチン-7-グルコシドのピーク面積/ヘスペリジンのピーク面積)<HPLC条件;カラム:CAPCELL PAK C18 SIZE 4.6mm×250mm(SHISEIDO)、溶離液:40%(v/v)アセトニトリル/0.1%リン酸水溶液、検出:280nm、流速:0.4ml/min、カラム温度:70℃>より、転化率(%)=ヘスペレチン-7-グルコシドのピ-ク面積×100/(ルチンのピ-ク面積+ヘスペレチン-7-グルコシドのピ-ク面積)として算出した。ヘスペレチン-7-グルコシドは、NMRによりヘスペレチン-7-グルコシドであることを確認した乾燥品を用いて、HPLCにて同一のピークであることで確認した。実施例17~31における転化率はいずれも96%以上であった。一方、比較例3における転化率は57%と低いものであった。
実施例101~109、及び比較例102の未濾過の反応終了混合液を測定サンプルとし、HPLC(SHIMADZU)の面積比(ナリンゲニン-7-グルコシドのピ-ク面積/ナリンジンのピ-ク面積)<HPLC条件;カラム:CAPCELL PAK C18 SIZE 4.6mm×250mm(SHISEIDO)、溶離液:25%(v/v)アセトニトリル/0.1%リン酸水溶液、検出:280nm、流速:0.4ml/min、カラム温度:70℃>より算出した。すなわち転化率(%)=ナリンゲニン-7-グルコシドのピ-ク面積×100/(ナリンジンのピ-ク面積+ナリンゲニン-7-グルコシドのピ-ク面積)として算出した。ナリンゲニン-7-グルコシドは、試薬ナリンゲニン-7-グルコシド(Wako)を用いてHPLCにて同一のピ-クであることで確認した。実施例101~109、及び比較例102の転化率は95%以上であった。
実施例1~16、比較例1、2、101の反応終了液を、室温静置後に、上清液1mlをフィルター濾過し、測定サンプルとした。試薬ルチン(Wako)を使用し吸光度351nm(0.1%リン酸溶液)で検量線を作成後、測定サンプルの吸光度よりルチン濃度を算出し、転化率で補正後0.761(イソクエルシトリン/ルチンの分子量比(464.38/610.52=0.761))を乗じたものをイソクエルシトリン濃度として算出した。結果を表1、1-2に示す。なお、濃度算出時の転化率は、濃度分析と同サンプルをHPLC測定後算出した。
実施例17~31、比較例3の反応終了液を、室温静置後に、上清液1mlをフィルター濾過し、測定サンプルとした。試薬ヘスペリジン(Wako)を使用した吸光度280nm(0.1%リン酸溶液)で検量線を作成後、測定サンプルの吸光度よりヘスペリジン濃度を算出し、HPLC分析の転化率で補正後、0.761(ヘスペレチン-7-グルコシド/ヘスペリジンの分子量比(464.42/610.56=0.761))を乗じたものをヘスペレチン-7-グルコシド濃度として算出した。結果を表2に示す。なお、濃度算出時の転化率は、濃度分析と同サンプルをHPLC測定後算出した。
実施例101~109、及び比較例102の反応終了液を、室温静置後に、上清液1mlをフィルター濾過し、測定サンプルとした。試薬ナリンジン(SIGMA社製、以下NRG)を使用した吸光度280nm(0.1%リン酸溶液)で検量線を作成後、測定サンプルの吸光度よりナリンジン濃度を算出し、HPLC分析の転化率で補正後、0.748(ナリンジン/ナリンゲニン-7-グルコシドの分子量比(434.39/580.54=0.748))を乗じたものをナリンゲニン-7-グルコシド濃度として算出した。結果を表2-2に示す。なお、濃度算出時の転化率は、濃度分析と同サンプルでHPLC測定後算出した。
実施例1~31、101~109及び比較例101の反応終了液を、室温静置後、上清液1mlをフィルターろ過し、測定サンプルとした。HPLC(SHIMADZU)分析<HPLC条件:カラム:Inertsil NH2(4.6×150mm(ジーエルサイエンス)、溶離液:65%アセトニトリル/水(v/v)、検出:示唆屈折計 RID-10A(SHIMADZU)、流速:1ml/min、カラム温度:40℃>より、β-シクロデキストリン(Wako)、γ-シクロデキストリン(Wako)の検量線を作成後、サンプルのシクロデキストリンのモル濃度を算出し、又イソクエルシトリン、ヘスペレチン-7-グルコシド、及びナリンゲニン-7-グルコシドのモル濃度とで、シクロデキストリン/イソクエルシトリン、シクロデキストリン/ヘスペレチン-7-グルコシド、シクロデキストリン/ナリンゲニン-7-グルコシドのモル比を算出した。結果を表1、1-2、2、2-2に示す。なお、反応終了後濾過液のモル比は、凍結乾燥物でも同じであった。
実施例1~31、101~109及び比較例1~3、101、102の反応終了液を、室温静置後、ろ紙濾過し、凍結乾燥により乾燥物を得た。水を50ml入れた100ml容量のビーカーの中に、上記で調製した乾燥物を、50℃で、撹拌しながら、溶解しきれず析出するまで添加した。室温(25℃)静置後、上清液1mlをフィルター濾過し、吸光度分析法にてイソクエルシトリン濃度、ヘスペレチン-7-グルコシド濃度、ナリンゲニン-7-グルコシド濃度を算出し、溶解度とした。但し、溶解度測定の際、乾燥物量が不充分である場合、同実施例実験を繰り返すことで必要量を取得し、溶解度を測定した。また、実施例1~31、101~109及び比較例101でフラボノイドがシクロデキストリンと包接されていることを、示差走査熱量計(DSC)、核磁気共鳴(NMR)、及びフーリエ変換赤外分光光度計(FT-IR)より確認した。溶解度の結果を表1、1-2、2、2-2に示す。なお、実施例1~31、101~109の反応終了後、室温ろ過液を、透析によりラムノースを除去したフラボノイド包接化合物の凍結乾燥物もほぼ同様の溶解度を示した。
(1)反応開始時のルチン濃度(質量%)
(2)反応開始時のβ-シクロデキストリン濃度(質量%)
(3)反応開始時のγ-シクロデキストリン濃度(質量%)
(4)反応開始時のデキストリン濃度(質量%)
(5)反応開始時のシクロデキストリン/ルチン(モル比)
(6)反応終了後濾過液のイソクエルシトリン濃度(質量%)
(7)反応終了後濾過液のシクロデキストリン/イソクエルシトリン(モル比)
(8)反応終了後濾過液凍結乾燥物のイソクエルシトリン溶解度(質量%)
(11)加熱撹拌開始時のイソクエルシトリン濃度(質量%)
(12)加熱撹拌開始時のγ-シクロデキストリン濃度(質量%)
(13)加熱撹拌開始時のシクロデキストリン/イソクエルシトリン(モル比)
(14)加熱撹拌後濾過液のイソクエルシトリン濃度(質量%)
(15)加熱撹拌後濾過液のシクロデキストリン/イソクエルシトリン(モル比)
(16)加熱撹拌後濾過液凍結乾燥物のイソクエルシトリン溶解度(質量%)
(21)反応開始時のヘスペリジン濃度(質量%)
(22)反応開始時のβ-シクロデキストリン濃度(質量%)
(23)反応開始時のγ-シクロデキストリン濃度(質量%)
(24)反応開始時のシクロデキストリン/ヘスペリジン(モル比)
(25)反応終了後濾過液のヘスペレチン-7-グルコシド濃度(質量%)
(26)反応終了後濾過液のシクロデキストリン/ヘスペレチン-7-グルコシド(モル比)
(27)反応終了後濾過液凍結乾燥物のヘスペレチン-7-グルコシド溶解度(質量%)
(31)反応開始時のナリンジン濃度(質量%)
(32)反応開始時のβ-シクロデキストリン濃度(質量%)
(33)反応開始時のシクロデキストリン/ナリンジン(モル比)
(34)反応終了後濾過液のナリンゲニン-7-グルコシド濃度(質量%)
(35)反応終了後濾過液のシクロデキストリン/ナリンゲニン-7-グルコシド(モル比)
(36)反応終了後濾過液凍結乾燥物のナリンゲニン-7-グルコシド溶解度(質量%)
また実施例18~25、27~31、101~109の反応終了後濾過液のラムノース含量を測定(HPLC糖分析法と同条件、ラムノース(Wako)で検量線作成)後、ラムノースのモル濃度を算出したところ、包接化合物のフラボノイドとのモル比(ラムノース/フラボノイド)は、0.8~1.2であった。
実施例10~15の反応終了液の各100mlを、透析膜(スペクトラ/ポア CE 透析用チューブ,MWCO 500-1000, funakoshi社製)に入れ、水10L中で透析(5回水交換、10℃)を行うことでラムノースを除去し、その後各液を凍結乾燥して10g~30gの乾燥物を得た。得られた乾燥物を、市販の炭酸飲料(無糖)(「南アルプスの天然水スパークリング」、サントリー社製)、コーヒー飲料(無糖)(「ワンダゴールド ブラック」、アサヒ飲料社製)、及びお茶(「おーいお茶」、伊藤園社製)にイソクエルシトリン換算濃度として0.1質量%添加し、5名のパネラーにより、無添加品を対照に、官能評価(異味、甘味)を実施した。下記の評価基準に従い、それぞれの平均点を算出した。結果を表3に示す。
1:異味を強く感じる
2:異味をやや強く感じる
3:異味を感じる
4:異味をかすかに感じる
5:異味を感じない
1:甘味を強く感じる
2:甘味をやや強く感じる
3:甘味を感じる
4:甘味をかすかに感じる
5:甘味を感じない
実施例32~39
実施例4で調製した反応液(70℃、pH4.5、イソクエルシトリン濃度2.3質量%)に、少量のアルカリを加えて60℃、pH6.5に調整後、シクロデキストリングルカノトランスフェラーゼ(CGTase :天野エンザイム(株)、商品名「コンチザイム」、600U/ml)20gを添加して反応を開始し、24時間保持した。得られた反応液を、加熱殺菌、濾過後、凍結乾燥して、一般式(1)で示される化合物を含むイソクエルシトリン配糖体組成物158g(試料1)を得た。得られたイソクエルシトリン配糖体組成物(試料1)における水への溶解度は、イソクエルシトリン換算値で2.7%であった。得られたイソクエルシトリン配糖体組成物(試料1)を水に溶解後、ダイヤイオンHP-20(多孔性合成吸着樹脂、三菱ケミカル社製)を充填したカラムに通液しイソクエルシトリン配糖体組成物を吸着させ、樹脂容量の2倍の水で洗浄することでラムノース等の糖類を除去した。その後、樹脂容量の2倍の65%(v/v)エタノールにより吸着成分を溶離させた溶出液を濃縮後、凍結乾燥して、実施例39の配糖体組成物を調製した。実施例39のHPLCクロマトグラムを図1に示す。この結果は、試料1のHPLCクロマトグラムと同等であった。また、実施例39と同様の方法で、イソクエルシトリン配糖体組成物 (試料1)を吸着、水洗浄後、溶出させるエタノール濃度を10~60%(v/v)で溶出させた。それら溶出液(10、20、30、40、50、60%(v/v)溶出液)を組み合わせてモル比調整した溶液を、濃縮後凍結乾燥して、実施例32~38の配糖体組成物を調製した。実施例32~39の配糖体組成物の水への溶解度は、イソクエルシトリン換算値で10%以上であった。なお、糖転移反応時、同酵素量で、pH7.5、pH8.5での反応液を調製したところ、ほぼ同量のイソクエルシトリン配糖体組成物が産生したが、フラボノイドの一部分解により、溶液の色目が褐黒色化したため、pH6.5で反応させたものを使用した。なお、実施例1~3、10~16で調製した反応液も、同条件で試料1と同じHPLCクロマトグラム(図1)のイソクエルシトリン配糖体組成物が作製された。
実施例22で調製した反応液(70℃、pH4.5、ヘスペレチン-7-グルコシド濃度2.9質量%)に、少量のアルカリを加えて60℃、pH6.5に調整後、シクロデキストリングルカノトランスフェラーゼ(CGTase :天野エンザイム(株)、商品名「コンチザイム」、600U/ml)5gを添加して反応を開始し、24時間保持した。得られた反応液を、加熱殺菌、濾過後、噴霧乾燥して、一般式(2)で示される化合物を含むヘスペレチン-7-グルコシド配糖体組成物136g(試料2)を得た。得られたヘスペレチン-7-グルコシド配糖体組成物(試料2)における水への溶解度は、ヘスペレチン-7-グルコシド換算値で5.1%であった。得られたヘスペレチン-7-グルコシド配糖体組成物(試料2)を水に溶解後、ダイヤイオンHP-20(多孔性合成吸着樹脂、三菱ケミカル社製)を充填したカラムに通液しヘスペレチン-7-グルコシド配糖体組成物を吸着させ、樹脂容量の2倍の水で洗浄することでラムノース等の糖類を除去した。その後、樹脂容量の2倍の65%(v/v)エタノールにより吸着成分を溶離させた溶出液を濃縮後、凍結乾燥して、実施例40の配糖体組成物を調製した。実施例40のHPLCクロマトグラムを図2に示す。この結果は、試料2のHPLCクロマトグラムと同等であった。また、実施例40と同様の方法で、ヘスペレチン-7-グルコシド配糖体組成物 (試料2)を吸着、水洗浄後、溶出させるエタノール濃度を10~60%(v/v)で溶出させた。それら溶出液(10、20、30、40、50、60%(v/v)溶出液)を組み合わせてモル比調整した溶液を、濃縮後凍結乾燥して、実施例41~46の配糖体組成物を調製した。実施例40~46の配糖体組成物の水への溶解度は、ヘスペレチン-7-グルコシド換算値で10%以上であった。なお、糖転移反応時、同酵素量で、pH7.5、pH8.5での反応液を調製したところ、ほぼ同量のヘスペレチン-7-グルコシド配糖体組成物が産生したが、フラボノイドの一部分解により、溶液の色目が褐黒色化したため、pH6.5で反応させたものを使用した。なお、実施例21、23、27~31で調製した反応液も、同条件で試料2と同じHPLCクロマトグラム(図2)のイソクエルシトリン配糖体組成物が作製された。
試料1、2、及び実施例32~46のフラボノイド配糖体組成物の溶解度は、前記IQC溶解度、HPT-7G溶解度と同法で、イソクエルシトリン濃度、ヘスペレチン-7-グルコシド濃度を算出し、イソクエルシトリン換算値、ヘスペレチン-7-グルコシド換算値とした。なお、各換算値が10%以上で析出が観察されないものは、溶解度を10%以上として記述した。
モル比(%)=フラボノイド配糖体組成物の各ピーク面積×100/フラボノイド配糖体組成物の総ピーク面積
カラム:CAPCELL PAK C18 SIZE 4.6mm×250mm(SHISEIDO)
溶離液:水/アセトニトリル/リン酸=799/200/1(体積比)
検出:波長351nmにおける吸光度測定
流速:0.4ml/min
カラム温度:70℃
カラム:CAPCELL PAK C18 SIZE 4.6mm×250mm(SHISEIDO)
溶離液:水/アセトニトリル/リン酸=849/150/1(体積比)
検出:波長280nmにおける吸光度測定
流速:0.4ml/min
カラム温度:70℃
実施例32~46のフラボノイド配糖体組成物の凍結乾燥物を、酸糖液(pH3.1、Brix10°)に、イソクエルシトリン換算濃度が0.05%(実施例32~39)、あるいはヘスペレチン-7-グルコシド換算濃度が0.05%(実施例40~46)になるように添加し、7名のパネラーにより官能評価(苦味、エグ味、収斂味)を実施した。下記の評価基準に従い、それぞれの平均点を算出した。なお、比較例101で調製したイソクエルシトリン0.05%含有酸糖液(調製直後溶解液)における苦味、エグ味、及び収斂味の評価点を最も強い1として比較した。またイソクエルシトリン0.05%含有酸糖液は、調製後室温にて30分は沈殿が観察されなかったため、その間に官能評価を実施した。結果を表4に示す。
1:苦味を強く感じる
2:苦味をやや強く感じる
3:苦味を感じる
4:苦味をかすかに感じる
5:苦味を感じない
1:エグ味を強く感じる
2:エグ味をやや強く感じる
3:エグ味を感じる
4:エグ味をかすかに感じる
5:エグ味を感じない
1:収斂味を強く感じる
2:収斂味をやや強く感じる
3:収斂味を感じる
4:収斂味をかすかに感じる
5:収斂味を感じない
試料1、及び試料2のラムノース含量測定(HPLC糖分析法と同条件、ラムノース(Wako)で検量線を作成)後に算出されたモル濃度とイソクエルシトリン換算値、ヘスペレチン-7-グルコシド換算値から算出したモル濃度とのモル比(ラムノース/フラボノイド)は、0.8~1.2であった。
実施例16のフラボノイド包接化合物含有組成物および実施例39のフラボノイド配糖体組成物を、赤キャベツ色素製剤0.05%含有酸糖液(pH3.0)に、イソクエルシトリン換算濃度が0.005%になるよう添加し、紫外線フェードメーター処理4時間後の色素残存率を比較したところ、無添加品と比べて退色防止効果が観察された。結果を表5に示す。
実施例16の反応終了液100mlを、透析膜(スペクトラ/ポア CE 透析用チューブ,MWCO 500-1000, funakoshi社製)に入れ、水10L中で透析(5回水交換、10℃)を行うことでラムノースを除去し、その溶液を凍結乾燥して22gの乾燥物を得た。得られた乾燥物および実施例39のフラボノイド配糖体組成物を、市販の牛乳(乳脂肪3.5%、「明治乳業」、明治社製)に、イソクエルシトリン換算濃度が0.005%になるよう100ml透明ガラス瓶に添加し、蛍光灯照射(20000ルクス、5時間、10℃)後の香味について、下記評価基準によりパネラー10名の平均点で比較したところ、香味劣化防止効果が観察された。結果を表6に示す。
1:未照射品より著しく変化している
2:未照射品よりかなり変化している
3:未照射品より少し変化している
4:未照射品と僅かに変化している
5:未照射品と変化なし
グレープフルーツ果汁(1/6)0.5%、ゼラチン3%、グレープフルーツさのう1%、マルチトール6%、ベニバナ黄色製剤0.025%を原料とする無添加品のグレープフルーツゼリーを調製した。実施例22、28の反応終了液100mlを、透析膜(スペクトラ/ポア CE 透析用チューブ,MWCO 500-1000, funakoshi社製)に入れ、水10L中で透析(5回水交換、10℃)を行うことでラムノースを除去し、その溶液を凍結乾燥して実施例22より12g、実施例28より16gの乾燥物を得た。得られた各乾燥物および実施例40のフラボノイド配糖体組成物を、ヘスペレチン-7-グルコシド換算濃度が0.005%になるように無添加品のグレープフルーツゼリーに添加し、添加品のグレープフルーツゼリーをそれぞれ調製した。その後93℃に加熱し、これらを透明ガラス瓶に密封後、冷却し、室温下、通常の蛍光灯の当たる部屋で、1か月保存した後の香味について、下記評価基準によりパネラー10名の平均点で比較したところ、各添加品に香味劣化防止効果が観察された。結果を表7に示す。
1:未照射品より著しく変化している
2:未照射品よりかなり変化している
3:未照射品より少し変化している
4:未照射品と僅かに変化している
5:未照射品と変化なし
比較例101で調製したイソクエルシトリン、実施例16のフラボノイド包接化合物含有組成物、および実施例39のフラボノイド配糖体組成物を、イソクエルシトリン換算濃度が0.03%となるように、下記組成からなるpH3の酸糖液に溶解し、100m1容のガラス瓶にホットパック充填(93℃)した。調製した溶液は放冷後、それぞれ4℃、25℃、40℃の条件下で4ヶ月間静置し、析出の有無を目視で観察した。透明で沈殿が観察されなかったものを○、沈殿が観察されたものを×とした。結果を表8に示す。
(質量%)
1.砂糖 10
2.クエン酸(結晶) 0.08
3.クエン酸3ナトリウム pHを調整(pH3)
4.水 残部
ヘスペリジン(浜理薬品工業株式会社製)、ヘスペレチン-7-グルコシド(下記で調製したもの)、実施例22のフラボノイド包接化合物、及び実施例40のフラボノイド配糖体組成物のヘスペレチン-7-グルコシド換算濃度が0.03%となるように、市販のお茶(「お~いお茶」、伊藤園社製)に添加し、4℃、25℃に7日間静置後、沈殿の有無を目視で観察した。透明で沈殿が観察されなかったものを○、沈殿が観察されたものを×とした。結果を表9に示す。
ナリンジン(SIGMA社製)、ナリンゲニン-7-グルコシド(下記で調製したもの)、実施例109のフラボノイド包接化合物含有組成物のナリンゲニン-7-グルコシド換算濃度が0.3%となるように、市販のレモン飲料(C1000レモンウォーター、ハウスウェルネスフーズ社製)に添加し、4℃、25℃に1ヶ月間静置後、沈殿の有無を目視で観察した。透明で沈殿が観察されなかったものを○、沈殿が観察されたものを×とした。結果を表9-2に示す。
9週齢のWisterラット(雄)に飼料として、MF(オリエンタル酵母(株))を与えて7日間飼育した後、試験物質投与前日より絶食下においた。その後、香味劣化防止効果の評価において調製した実施例16の乾燥物100μmol/kg(IQC換算値)、ルチン懸濁液(アルプス薬品工業、100μmol/kg(IQC換算値))、香味劣化防止効果の評価において調製した実施例22の乾燥物1000μmol/kg(HPT-7G換算値)、ヘスペリジン懸濁液(浜理薬品工業株式会社、1000μmol/kg(HPT-7G換算値))を単回経口投与(ゾンデ強制経口投与、n=2)し、30分後、1時間後、3時間後において、ラット尾静脈よりヘパリン採血し、遠心分離し血漿を得た。採取した血清試料中のケルセチン誘導体量は牧野らの方法(Biol.pharm.Bull.32(12) 2034,2009)、ヘスペレチン誘導体量は、山田らの方法(Biosci. Biotechnol. Biochem, 70(6),1386,2006)に準じ、高速液体クロマトグラフィー(SHIMADZU)にかけ、フォトダイオードアレイ検出器(SPD-M30A,SHIMADZU)を使用して分析した。結果を表10、11に示す。表10には、0~3時間のケルセチン及びケルセチン誘導体(イソラムネチン、タマリキセチン)の濃度(μM)、及びそれらの総和の血中濃度時間曲線下面積(AUC)(μM・h)を示した。また、表11には、ヘスペレチン誘導体は検出されなかったため、0~3時間のヘスペレチン濃度(μM)、及びその血中濃度時間曲線下面積(AUC)(μM・h)を示した。
実施例110~113
表12に示す成分用量でルチン(RTN)及びイソクエルシトリンとγ-シクロデキストリンとの包接化合物(IQC-rCD)を酸糖液(pH3.1、Brix10°)に溶解し、100mlのガラス瓶にホットパック充填した。調製した溶液を放冷し、冷蔵保存(4℃、6ヶ月)後、沈殿の有無を目視観察した。結果を表12に示す。
表13に示す成分用量でルチン(RTN)及びイソクエルシトリン(IQC)を酸糖液に溶解した以外は実施例110~113と同様にして調製、放冷、冷蔵保存し、沈殿の有無を目視観察した。結果を表13に示す。
(41)酸糖液中のルチン濃度 (質量%)
(42)酸糖液中のイソクエルシトリン-γ-シクロデキストリン包接化合物濃度(質量%)
(43)酸糖液中のイソクエルシトリン濃度(質量%)
(44)酸糖液中のγ-シクロデキストリン濃度(質量%)
(45)溶解性:
沈殿が観察されない :-
沈殿の量が少ない :+
沈殿の量がやや多い :++
沈殿の量が多い :+++
(46)酸糖液中のイソクエルシトリン/ルチン(モル比)
実施例114~117
表14に示す成分用量とした以外は実施例110~113と同様に溶液を調製し、放冷直後に収斂味について官能評価を行った。また同成分用量のものを別調製し、冷蔵保存(4℃、12ヶ月)後、沈殿の有無を目視観察した。結果を表14に示す。
表15に示す成分用量とした以外は比較例103~106と同様に溶液を調製し、放冷直後に収斂味について官能評価を行った。また同成分用量のものを別調製し、冷蔵保存(4℃、12ヶ月)後、沈殿の有無を目視観察した。結果を表15に示す。
(51)酸糖液中のイソクエルシトリン-γ-シクロデキストリン包接化合物濃度(質量%)
(52)酸糖液中のイソクエルシトリン濃度(質量%)
(53)酸糖液中のγ-シクロデキストリン濃度(質量%)
(54)酸糖液中のルチン濃度 (質量%)
(55)溶解性:
沈殿が観察されない :-
沈殿の量が少ない :+
沈殿の量がやや多い :++
沈殿の量が多い :+++
(56)酸糖液中のルチン/イソクエルシトリン(モル比)
(57)酸糖液調製放冷直後、10名のパネラーにより、無添加の酸糖液と比較し、最も強く収斂味を感じたサンプルを3点とし、以下、2点、1点とし、その平均を示した。
尚、比較例107~110は調製放冷後、室温にて30分間は沈殿が観察されなかった為、その間に官能評価を実施した。
RTN:99.5%容量エタノール90gとルチン(調製品:イソクエルシトリン/ルチンのモル比が0.3/99.7)10gとの加熱溶解品
IQC-rCD:実施例16の凍結乾燥品(透析によるラムノース除去品、(ルチン/イソクエルシトリンのモル比が0.3/99.7))
IQC:99.5%容量エタノール18gとイソクエルシトリン(調製品:ルチン/イソクエルシトリンのモル比が0.3/99.7)2gとの加熱溶解品
処方例1:グレープフルーツ飲料
香味劣化防止の為、実施例16のイソクエルシトリン・γ-シクロデキストリン包接化合物含有組成物の乾燥物を含有する飲料を調製した。本品は、飲料として、好適に利用できる。
グレープフルーツ濃縮果汁 5.0
ブドウ糖果糖混合液糖 0.9
マルチトール 2.0
酸味料 0.3
ビタミンC 0.02
香料 0.1
実施例16の乾燥物 0.02
水 残部
合計 100
香味劣化防止の為、実施例22のヘスペレチン-7-グルコシド・β-シクロデキストリン包接化合物含有組成物の乾燥物を含有するゼリーを調製した。本品は、食品(ゼリー)として、好適に利用できる。
砂糖 10.0
レモン濃縮果汁 8.5
クチナシ黄色製剤 0.004
酸味料 1.0
ゲル化剤 1.5
ビタミンC 0.02
香料 0.2
実施例22の乾燥物 0.04
水 残部
合計 100
くすみやむくみの肌改善の為、実施例40のヘスペレチン-7-グルコシド配糖体組成物の乾燥物を含有する化粧品を調製した。本品は、スキンケア化粧品として、好適に利用できる。
グリセリン 5.0
プロピレングリコール 4.0
オレイルアルコール 0.1
界面活性剤 2.0
エチルアルコール 10.0
香料 0.1
実施例40の乾燥物 0.26
精製水 残部
合計 100
体温緩和の為、実施例22のヘスペレチン-7-グルコシド・β-シクロデキストリン包接化合物含有組成物の乾燥物を含有する錠剤を調製した。本品は、健康食品として、好適に使用できる。
マルチトール 69.0
トレハロース 12.9
酸味料 2.5
ステアリン酸Ca 0.5
ビタミンC 0.02
香料 0.08
実施例22の乾燥物 15.0
合計 100
体脂肪減小の為、実施例39のイソクエルシトリン配糖体組成物の乾燥物を含有するコーヒー飲料を調製した。本品は、特定保健用食品として好適に利用できる。
コーヒー抽出物 32.6
砂糖 6.0
香料 0.06
実施例39の乾燥物 0.06
水 残部
合計 100
中性脂肪減小の為、実施例40のヘスペレチン-7-グルコシド配糖体組成物の乾燥物を含有する紅茶飲料を調製した。本品は、機能性表示食品として好適に利用できる。
紅茶抽出液 18.6
炭酸水素ナトリウム 0.002
スクラロース 0.003
ビタミンC 0.03
香料 0.1
実施例40の乾燥物 0.06
水 残部
合計 100
頭皮改善のため、実施例22のヘスペレチン-7-グルコシド・β-シクロデキストリン包接化合物含有組成物の乾燥物を含有する育毛剤を調製した。
エチルアルコール 60.0
センブリエキス 5.0
酢酸トコフェロール 0.2
パントテニルエチルエーテル 0.2
プロピレングリコール 5.0
防腐剤 0.1
香料 0.2
実施例22の乾燥物 0.03
精製水 残部
合計 100
炎症予防のため、実施例27のヘスペレチン-7-グルコシド・γ-シクロデキストリン包接化合物含有組成物の乾燥物を含有するヘアシャンプーを調製した。
ポリオキシエチレン(2)ラウリルエーテル
硫酸ナトリウム 9.0
ラウリル硫酸ナトリウム 4.0
ヤシ油脂肪酸アミドプロピルベタイン 3.0
高重合メチルポリシロキサン 2.0
メチルポリシロキサン 1.0
ヤシ油脂肪酸モノエタノールアミド 1.0
プロピレングリコール 2.0
ジステアリン酸エチレングリコール 2.0
防腐剤 0.1
香料 0.1
実施例27の乾燥物 0.03
水 残部
合計 100
ダイエットの為、実施例109のナリンゲニン-7-グルコシド-β-シクロデキストリン包接化合物含有組成物の乾燥物を含有する錠剤を調製した。本品は、健康食品として、好的に利用できる。
マルチトール 64.0
トレハロース 12.9
酸味料 2.5
ステアリン酸Ca 0.5
ビタミンC 0.02
香料 0.08
実施例109の乾燥物 20.0
合計 100
Claims (34)
- ラムノシド構造をもつ難溶性フラボノイドを、シクロデキストリンの存在下、ラムノシダーゼ活性を有する酵素で処理してラムノースを脱離する脱離工程を含む、フラボノイド包接化合物の製造方法。
- 前記ラムノシド構造をもつ難溶性フラボノイドが、ルチン、ヘスペリジン、ナリルチン、ナリンジン、ジオスミン、エリオシトリン、ミリシトリン、ネオヘスペリジン、ルテオリン-7-ルチノシド、デルフィニジン-3-ルチノシド、シアニジン-3-ルチノシド、イソラムネチン-3-ルチノシド、ケンペロール-3-ルチノシド、アピゲニン-7-ルチノシド、及びアカセチン-7-ルチノシドからなる群より選択される1種以上である、請求項1記載の製造方法。
- 前記シクロデキストリンが、β-シクロデキストリン、分枝β-シクロデキストリン、及びγ-シクロデキストリンからなる群より選択される1種以上である、請求項1又は2記載の製造方法。
- 前記ラムノシド構造をもつ難溶性フラボノイド1モルに対し、前記シクロデキストリンを0.01モル以上の割合で存在させる、請求項1~3いずれか記載の製造方法。
- 前記脱離工程がpH3~7の水媒体において行われる、請求項1~4いずれか記載の製造方法。
- 前記フラボノイド包接化合物が、前記ラムノシド構造をもたない難溶性フラボノイドがシクロデキストリンに包接されたフラボノイド包接化合物であり、前記ラムノシド構造をもたない難溶性フラボノイドと前記シクロデキストリンとのモル比(シクロデキストリン/フラボノイド)が1.0~3.0である、請求項1~5いずれか記載の製造方法。
- 前記フラボノイド包接化合物が、イソクエルシトリンがγ-シクロデキストリンに包接されたフラボノイド包接化合物であり、前記イソクエルシトリンと前記γ-シクロデキストリンとのモル比(γ-シクロデキストリン/イソクエルシトリン)が0.9~4.0である、請求項1~6いずれか記載の製造方法。
- 前記フラボノイド包接化合物が、イソクエルシトリンがγ-シクロデキストリンに包接されたフラボノイド包接化合物であり、前記イソクエルシトリンと前記γ-シクロデキストリンとのモル比(γ-シクロデキストリン/イソクエルシトリン)が0.9~1.8である、請求項1~7いずれか記載の製造方法。
- 前記フラボノイド包接化合物が、イソクエルシトリンがβ-シクロデキストリンに包接されたフラボノイド包接化合物であり、前記イソクエルシトリンと前記β-シクロデキストリンとのモル比(β-シクロデキストリン/イソクエルシトリン)が1.0~3.0である、請求項1~6いずれか記載の製造方法。
- 前記フラボノイド包接化合物が、ヘスペレチン-7-グルコシドがシクロデキストリンに包接されたフラボノイド包接化合物であり、前記ヘスペレチン-7-グルコシドと前記シクロデキストリンとのモル比(シクロデキストリン/ヘスペレチン-7-グルコシド)が1.0~3.0である、請求項1~6いずれか記載の製造方法。
- 前記フラボノイド包接化合物が、ナリンゲニン-7-グルコシドがβ-シクロデキストリンに包接されたフラボノイド包接化合物であり、前記ナリンゲニン-7-グルコシドと前記β-シクロデキストリンとのモル比(β-シクロデキストリン/ナリンゲニン-7-グルコシド)が1.0~3.0である、請求項1~6いずれか記載の製造方法。
- 得られるイソクエルシトリン包接化合物は体内吸収性が向上したものである、請求項7~9いずれか記載の製造方法。
- 得られるヘスペレチン-7-グルコシド包接化合物は体内吸収性が向上したものである、請求項10記載の製造方法。
- 請求項1~13いずれか記載の製造方法により得られたフラボノイド包接化合物を糖転移酵素で処理して配糖体化する配糖体化工程を含む、フラボノイド配糖体組成物の製造方法。
- 前記配糖体化工程がpH3~7の水媒体において行われる、請求項14記載の製造方法。
- ラムノシド構造をもつ難溶性フラボノイドを、シクロデキストリンの存在下、ラムノシダーゼ活性を有する酵素で処理してラムノースを脱離する脱離工程、及び前記脱離工程を経て得られたフラボノイド包接化合物を糖転移酵素で処理して配糖体化する配糖体化工程を含む、フラボノイド配糖体組成物の製造方法。
- イソクエルシトリンがγ-シクロデキストリンに包接されたフラボノイド包接化合物であって、前記イソクエルシトリンと前記γ-シクロデキストリンとのモル比(γ-シクロデキストリン/イソクエルシトリン)が0.9~1.8であり、前記イソクエルシトリンの水への溶解度が2%以上である、フラボノイド包接化合物。
- イソクエルシトリンがγ-シクロデキストリンに包接されたフラボノイド包接化合物であって、前記イソクエルシトリンと前記γ-シクロデキストリンとのモル比(γ-シクロデキストリン/イソクエルシトリン)が0.9~4.0であり、前記イソクエルシトリンの水への溶解度が2.5%以上である、フラボノイド包接化合物。
- 前記イソクエルシトリンと前記γ-シクロデキストリンとのモル比(γ-シクロデキストリン/イソクエルシトリン)が1.0~1.8であり、甘味が低減されている、請求項17又は18記載のフラボノイド包接化合物。
- イソクエルシトリンがβ-シクロデキストリンに包接されたフラボノイド包接化合物であって、前記イソクエルシトリンと前記β-シクロデキストリンとのモル比(β-シクロデキストリン/イソクエルシトリン)が1.0~3.0であり、前記イソクエルシトリンの水への溶解度が0.1%以上である、フラボノイド包接化合物。
- ヘスペレチン-7-グルコシドがシクロデキストリンに包接されたフラボノイド包接化合物であって、前記ヘスペレチン-7-グルコシドと前記シクロデキストリンとのモル比(シクロデキストリン/ヘスペレチン-7-グルコシド)が1.0~3.0であり、前記ヘスペレチン-7-グルコシドの水への溶解度が0.01%以上である、フラボノイド包接化合物。
- 前記ヘスペレチン-7-グルコシドと前記シクロデキストリンとのモル比(シクロデキストリン/ヘスペレチン-7-グルコシド)が1.0~1.9であり、甘味が低減されている、請求項21記載のフラボノイド包接化合物。
- ナリンゲニン-7-グルコシドがβ-シクロデキストリンに包接されたフラボノイド包接化合物であって、前記ナリンゲニン-7-グルコシドと前記β-シクロデキストリンとのモル比(β-シクロデキストリン/ナリンゲニン-7-グルコシド)が1.0~3.0であり、前記ナリンゲニン-7-グルコシドの水への溶解度が0.01%以上である、フラボノイド包接化合物。
- 請求項17~23いずれか記載のフラボノイド包接化合物とラムノースとを含み、前記フラボノイド包接化合物中のフラボノイドと前記ラムノースとのモル比(ラムノース/フラボノイド)が0.8~1.2である、フラボノイド包接化合物含有組成物。
- 請求項17~23いずれか記載のフラボノイド包接化合物と、ラムノシド構造をもつ難溶性フラボノイドとを含み、前記フラボノイド包接化合物中のフラボノイドと前記難溶性フラボノイドとのモル比(難溶性フラボノイド/包接化合物中のフラボノイド)が0.001~0.1である、フラボノイド包接化合物含有組成物。
- 苦味が低減された、請求項26記載のイソクエルシトリン配糖体組成物。
- 苦味が低減された、請求項28記載のヘスペレチン-7-グルコシド配糖体組成物。
- 請求項1~13いずれか記載の製造方法により得られたフラボノイド包接化合物、請求項14~16いずれか記載の製造方法により得られたフラボノイド配糖体組成物、請求項17~23いずれか記載のフラボノイド包接化合物、請求項24又は25記載のフラボノイド包接化合物含有組成物、請求項26又は27記載のイソクエルシトリン配糖体組成物、請求項28又は29記載のヘスペレチン-7-グルコシド配糖体組成物、及び請求項30記載のナリンゲニン-7-グルコシド配糖体組成物からなる群より選択される1種以上の化合物又は組成物を含む、飲食品。
- 請求項1~13いずれか記載の製造方法により得られたフラボノイド包接化合物、請求項14~16いずれか記載の製造方法により得られたフラボノイド配糖体組成物、請求項17~23いずれか記載のフラボノイド包接化合物、請求項24又は25記載のフラボノイド包接化合物含有組成物、請求項26又は27記載のイソクエルシトリン配糖体組成物、請求項28又は29記載のヘスペレチン-7-グルコシド配糖体組成物、及び請求項30記載のナリンゲニン-7-グルコシド配糖体組成物からなる群より選択される1種以上の化合物又は組成物を含む、医薬品。
- 請求項1~13いずれか記載の製造方法により得られたフラボノイド包接化合物、請求項14~16いずれか記載の製造方法により得られたフラボノイド配糖体組成物、請求項17~23いずれか記載のフラボノイド包接化合物、請求項24又は25記載のフラボノイド包接化合物含有組成物、請求項26又は27記載のイソクエルシトリン配糖体組成物、請求項28又は29記載のヘスペレチン-7-グルコシド配糖体組成物、及び請求項30記載のナリンゲニン-7-グルコシド配糖体組成物からなる群より選択される1種以上の化合物又は組成物を含む、化粧品。
- ラムノシド構造をもつ難溶性フラボノイドと、請求項1~13いずれか記載の製造方法により得られたフラボノイド包接化合物あるいは請求項17~23いずれか記載のフラボノイド包接化合物とを、前記フラボノイド包接化合物中のフラボノイドと前記難溶性フラボノイドとのモル比(包接化合物中のフラボノイド/難溶性フラボノイド)が0.1~0.9となるように媒体中で混合する、ラムノシド構造をもつ難溶性フラボノイドの溶解性を向上させる方法。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/097,120 US10519182B2 (en) | 2017-07-28 | 2018-01-31 | Method for producing flavonoid inclusion compound |
EP20177398.3A EP3733860A1 (en) | 2017-07-28 | 2018-01-31 | Flavonoid inclusion compounds |
EP18799420.7A EP3453766B1 (en) | 2017-07-28 | 2018-01-31 | Method for producing flavonoid inclusion compounds |
CA3052025A CA3052025C (en) | 2017-07-28 | 2018-01-31 | Method for producing flavonoid clathrate |
ES18799420T ES2806737T3 (es) | 2017-07-28 | 2018-01-31 | Método de producción de compuestos de inclusión de flavonoide |
KR1020207001761A KR102194884B1 (ko) | 2017-07-28 | 2018-01-31 | 플라보노이드 포접 화합물의 제조 방법 |
PL18799420T PL3453766T3 (pl) | 2017-07-28 | 2018-01-31 | Sposób wytwarzania związków inkluzyjnych flawonoidów |
JP2018526605A JP6421280B1 (ja) | 2017-07-28 | 2018-01-31 | フラボノイド包接化合物の製造方法 |
BR112020001069A BR112020001069A2 (pt) | 2017-07-28 | 2018-01-31 | método para produção de clatrato de flavonoide |
CN201880023105.5A CN110462052A (zh) | 2017-07-28 | 2018-01-31 | 黄酮包合化合物的制造方法 |
US16/669,753 US10676496B2 (en) | 2017-07-28 | 2019-10-31 | Method for producing flavonoid inclusion compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017147121 | 2017-07-28 | ||
JP2017-147121 | 2017-07-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/097,120 A-371-Of-International US10519182B2 (en) | 2017-07-28 | 2018-01-31 | Method for producing flavonoid inclusion compound |
US16/669,753 Division US10676496B2 (en) | 2017-07-28 | 2019-10-31 | Method for producing flavonoid inclusion compound |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019021510A1 true WO2019021510A1 (ja) | 2019-01-31 |
Family
ID=65039509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/003177 WO2019021510A1 (ja) | 2017-07-28 | 2018-01-31 | フラボノイド包接化合物の製造方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US10519182B2 (ja) |
EP (2) | EP3453766B1 (ja) |
JP (3) | JP6421280B1 (ja) |
KR (1) | KR102194884B1 (ja) |
CN (1) | CN110462052A (ja) |
BR (1) | BR112020001069A2 (ja) |
CA (1) | CA3052025C (ja) |
ES (1) | ES2806737T3 (ja) |
HU (1) | HUE049606T2 (ja) |
PL (1) | PL3453766T3 (ja) |
WO (1) | WO2019021510A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7454958B2 (ja) | 2019-03-01 | 2024-03-25 | 株式会社ダイセル | フラボノイド類の製造方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE049606T2 (hu) | 2017-07-28 | 2020-09-28 | Taiyo Kagaku Kk | Eljárás flavonoid inklúziós vegyületek elõállítására |
TWI761672B (zh) | 2018-04-23 | 2022-04-21 | 日商阿爾卑斯藥品工業股份有限公司 | O-醣苷基類黃酮之組成物 |
CN112236525A (zh) | 2018-06-01 | 2021-01-15 | 太阳化学株式会社 | 含有类黄酮-环糊精包合物的组合物 |
JP6727386B1 (ja) * | 2019-04-22 | 2020-07-22 | 三栄源エフ・エフ・アイ株式会社 | 香料組成物、及びその製造方法 |
US10918654B1 (en) * | 2019-09-23 | 2021-02-16 | Alps Pharmaceutical Ind. Co., Ltd. | Rutin compositions |
US11110109B2 (en) | 2019-10-22 | 2021-09-07 | Alps Pharmaceutical Ind. Co., Ltd. | Water soluble O-glycosyl flavonoid compositions and methods for preparing same |
CN113373168B (zh) * | 2021-06-22 | 2023-04-28 | 山西医科大学 | 细菌来源的α-L-鼠李糖苷酶基因、基因表达及其应用 |
CN114686549A (zh) * | 2022-04-29 | 2022-07-01 | 陕西嘉禾生物科技股份有限公司 | 一种利用芦丁制备酶改性异槲皮素的方法 |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS492151B1 (ja) | 1970-11-18 | 1974-01-18 | ||
JPS50373B1 (ja) | 1970-05-20 | 1975-01-08 | ||
JPS50884B2 (ja) | 1971-09-16 | 1975-01-13 | ||
JPS502072B1 (ja) | 1969-12-31 | 1975-01-23 | ||
JPH05310776A (ja) * | 1991-08-12 | 1993-11-22 | Wakayama Aguri Bio Kenkyu Center:Kk | 新規フラボノイド類 |
JPH0710898A (ja) | 1993-06-24 | 1995-01-13 | Sanei Gen F F I Inc | 水難溶性フラボノイドの改質方法 |
JPH07107972A (ja) * | 1993-10-13 | 1995-04-25 | Ezaki Glico Co Ltd | 可溶性フラボノイド類の製造方法 |
JP3135912B2 (ja) | 1990-11-27 | 2001-02-19 | 日本食品化工株式会社 | ルチン包接複合体及びその製造法 |
JP2003261593A (ja) * | 2002-03-08 | 2003-09-19 | Toyo Seito Kk | 酵素処理イソケルシトリン組成物 |
WO2005030975A1 (ja) * | 2003-09-29 | 2005-04-07 | San-Ei Gen F.F.I., Inc. | α-グリコシルイソクエルシトリン、並びにその製造中間体及び副生成物の調製方法 |
WO2006070883A1 (ja) * | 2004-12-28 | 2006-07-06 | Suntory Limited | クエルセチン配糖体組成物およびその調製方法 |
JP3833775B2 (ja) | 1996-06-26 | 2006-10-18 | 株式会社林原生物化学研究所 | 酵素処理ヘスペリジンおよびその製造方法ならびに酵素処理ヘスペリジンの使用方法 |
JP2008271839A (ja) * | 2007-04-27 | 2008-11-13 | Toyo Seito Kk | 水溶性フラボノイド組成物およびその製造方法、ならびに水溶性フラボノイド組成物を含む食品等 |
JP4202439B2 (ja) | 1996-10-01 | 2008-12-24 | 江崎グリコ株式会社 | フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液 |
WO2010110328A1 (ja) * | 2009-03-25 | 2010-09-30 | 三栄源エフ・エフ・アイ株式会社 | 水易溶性イソクエルシトリン組成物 |
JP2011225586A (ja) | 2003-07-02 | 2011-11-10 | Fuji Oil Co Ltd | フラボノイドの可溶化剤及び可溶化方法 |
JP2013215155A (ja) * | 2012-04-11 | 2013-10-24 | Kao Corp | 難水溶性ポリフェノール類の糖付加物の製造方法 |
JP2015188450A (ja) * | 2014-03-27 | 2015-11-02 | インターナショナル フレーバーズ アンド フラグランシズ インコーポレイテッド | 甘味増強用のナリンゲニン及びその塩 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60126400A (ja) | 1983-12-13 | 1985-07-05 | 帝人株式会社 | 耐熱紙 |
SE528108C2 (sv) | 2004-07-13 | 2006-09-05 | Sandvik Intellectual Property | Belagt hårdmetallskär, speciellt för svarvning av stål, samt sätt att tillverka detsamma |
JP5000884B2 (ja) | 2004-12-02 | 2012-08-15 | 江崎グリコ株式会社 | へスペレチン包接化合物およびナリンゲニン包接化合物の合成方法 |
JP4902151B2 (ja) | 2005-08-01 | 2012-03-21 | 株式会社林原生物化学研究所 | ヘスペレチン−7−β−マルトシド及びその製造方法並びにその用途 |
JP3135912U (ja) | 2007-07-20 | 2007-10-04 | 株式会社パイプシステム新潟 | パイプ連結構造 |
HUE049606T2 (hu) * | 2017-07-28 | 2020-09-28 | Taiyo Kagaku Kk | Eljárás flavonoid inklúziós vegyületek elõállítására |
-
2018
- 2018-01-31 HU HUE18799420A patent/HUE049606T2/hu unknown
- 2018-01-31 WO PCT/JP2018/003177 patent/WO2019021510A1/ja active Application Filing
- 2018-01-31 JP JP2018526605A patent/JP6421280B1/ja active Active
- 2018-01-31 ES ES18799420T patent/ES2806737T3/es active Active
- 2018-01-31 PL PL18799420T patent/PL3453766T3/pl unknown
- 2018-01-31 CA CA3052025A patent/CA3052025C/en active Active
- 2018-01-31 KR KR1020207001761A patent/KR102194884B1/ko active IP Right Grant
- 2018-01-31 BR BR112020001069A patent/BR112020001069A2/pt not_active Application Discontinuation
- 2018-01-31 CN CN201880023105.5A patent/CN110462052A/zh active Pending
- 2018-01-31 US US16/097,120 patent/US10519182B2/en active Active
- 2018-01-31 EP EP18799420.7A patent/EP3453766B1/en active Active
- 2018-01-31 EP EP20177398.3A patent/EP3733860A1/en not_active Withdrawn
- 2018-10-15 JP JP2018194031A patent/JP6539773B2/ja active Active
-
2019
- 2019-04-04 JP JP2019071906A patent/JP6925381B2/ja active Active
- 2019-10-31 US US16/669,753 patent/US10676496B2/en active Active
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS502072B1 (ja) | 1969-12-31 | 1975-01-23 | ||
JPS50373B1 (ja) | 1970-05-20 | 1975-01-08 | ||
JPS492151B1 (ja) | 1970-11-18 | 1974-01-18 | ||
JPS50884B2 (ja) | 1971-09-16 | 1975-01-13 | ||
JP3135912B2 (ja) | 1990-11-27 | 2001-02-19 | 日本食品化工株式会社 | ルチン包接複合体及びその製造法 |
JPH05310776A (ja) * | 1991-08-12 | 1993-11-22 | Wakayama Aguri Bio Kenkyu Center:Kk | 新規フラボノイド類 |
JPH0710898A (ja) | 1993-06-24 | 1995-01-13 | Sanei Gen F F I Inc | 水難溶性フラボノイドの改質方法 |
JPH07107972A (ja) * | 1993-10-13 | 1995-04-25 | Ezaki Glico Co Ltd | 可溶性フラボノイド類の製造方法 |
JP3989561B2 (ja) | 1993-10-13 | 2007-10-10 | 江崎グリコ株式会社 | 可溶性フラボノイド類の製造方法 |
JP3833775B2 (ja) | 1996-06-26 | 2006-10-18 | 株式会社林原生物化学研究所 | 酵素処理ヘスペリジンおよびその製造方法ならびに酵素処理ヘスペリジンの使用方法 |
JP4202439B2 (ja) | 1996-10-01 | 2008-12-24 | 江崎グリコ株式会社 | フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液 |
JP2003261593A (ja) * | 2002-03-08 | 2003-09-19 | Toyo Seito Kk | 酵素処理イソケルシトリン組成物 |
JP2011225586A (ja) | 2003-07-02 | 2011-11-10 | Fuji Oil Co Ltd | フラボノイドの可溶化剤及び可溶化方法 |
JP4498277B2 (ja) | 2003-09-29 | 2010-07-07 | 三栄源エフ・エフ・アイ株式会社 | α−グリコシルイソクエルシトリン、並びにその製造中間体及び副生成物の調製方法 |
WO2005030975A1 (ja) * | 2003-09-29 | 2005-04-07 | San-Ei Gen F.F.I., Inc. | α-グリコシルイソクエルシトリン、並びにその製造中間体及び副生成物の調製方法 |
WO2006070883A1 (ja) * | 2004-12-28 | 2006-07-06 | Suntory Limited | クエルセチン配糖体組成物およびその調製方法 |
JP2008271839A (ja) * | 2007-04-27 | 2008-11-13 | Toyo Seito Kk | 水溶性フラボノイド組成物およびその製造方法、ならびに水溶性フラボノイド組成物を含む食品等 |
WO2010110328A1 (ja) * | 2009-03-25 | 2010-09-30 | 三栄源エフ・エフ・アイ株式会社 | 水易溶性イソクエルシトリン組成物 |
JP2013215155A (ja) * | 2012-04-11 | 2013-10-24 | Kao Corp | 難水溶性ポリフェノール類の糖付加物の製造方法 |
JP5985229B2 (ja) | 2012-04-11 | 2016-09-06 | 花王株式会社 | 難水溶性ポリフェノール類の糖付加物の製造方法 |
JP2015188450A (ja) * | 2014-03-27 | 2015-11-02 | インターナショナル フレーバーズ アンド フラグランシズ インコーポレイテッド | 甘味増強用のナリンゲニン及びその塩 |
Non-Patent Citations (8)
Title |
---|
AMERICAN JOURNAL OF PHYSIOLOGY: GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol. 279, 2000, pages 1148 - 1154 |
BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 32, no. 12, 2009, pages 2034 - 2040 |
BRITISH JOURNAL OF NUTRITION, vol. 102, 2009, pages 976 - 984 |
JOURNAL OF NATURAL MEDICINES, vol. 67, no. 4, October 2013 (2013-10-01), pages 881 - 6 |
MAKINO ET AL., BIOI. PHARM. BULL., vol. 32, no. 12, 2009, pages 2034 |
PLOS ONE, vol. 4, 2011, pages e18033 |
See also references of EP3453766A4 * |
YAMADA ET AL., BIOSCI. BIOTECHNOL. BIOCHEM, vol. 70, no. 6, 2006, pages 1386 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7454958B2 (ja) | 2019-03-01 | 2024-03-25 | 株式会社ダイセル | フラボノイド類の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US20200062796A1 (en) | 2020-02-27 |
KR102194884B1 (ko) | 2020-12-24 |
US10676496B2 (en) | 2020-06-09 |
US10519182B2 (en) | 2019-12-31 |
JP6421280B1 (ja) | 2018-11-07 |
JP6925381B2 (ja) | 2021-08-25 |
JPWO2019021510A1 (ja) | 2019-08-08 |
JP2019134714A (ja) | 2019-08-15 |
EP3733860A1 (en) | 2020-11-04 |
EP3453766A1 (en) | 2019-03-13 |
JP6539773B2 (ja) | 2019-07-03 |
BR112020001069A2 (pt) | 2020-05-19 |
EP3453766B1 (en) | 2020-06-03 |
HUE049606T2 (hu) | 2020-09-28 |
JP2019024500A (ja) | 2019-02-21 |
KR20200013060A (ko) | 2020-02-05 |
CA3052025A1 (en) | 2019-01-31 |
PL3453766T3 (pl) | 2020-11-16 |
ES2806737T3 (es) | 2021-02-18 |
CA3052025C (en) | 2020-05-12 |
EP3453766A4 (en) | 2019-07-17 |
CN110462052A (zh) | 2019-11-15 |
US20190248825A1 (en) | 2019-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6539773B2 (ja) | フラボノイド包接化合物の製造方法 | |
JP3896577B2 (ja) | クエルセチン配糖体組成物およびその調製方法 | |
JP5000884B2 (ja) | へスペレチン包接化合物およびナリンゲニン包接化合物の合成方法 | |
JP3060227B2 (ja) | α―グリコシル ヘスペリジンとその製造方法並びに用途 | |
JP3134233B2 (ja) | α−グリコシル ケルセチンとその製造方法並びに用途 | |
JP5000373B2 (ja) | 水溶性フラボノイド組成物およびその製造方法、ならびに水溶性フラボノイド組成物を含む食品等 | |
KR0165956B1 (ko) | 알파-글리코실 루틴을 함유시킨 음식물의 제조방법 | |
JP4790561B2 (ja) | フラボノイド組成物、その製造方法および用途 | |
CN112236525A (zh) | 含有类黄酮-环糊精包合物的组合物 | |
JP7107855B2 (ja) | 経口摂取のためのステビオール配糖体組成物または使用 | |
JP4907122B2 (ja) | 水溶性ナリンジン組成物 | |
JPH0327293A (ja) | α―グリコシル ルチンの製造方法とその用途 | |
JP4846141B2 (ja) | 即効性および持続性を有するフラボノイド配糖体を含有する経口栄養補給剤 | |
JP3549436B2 (ja) | α−グリコシルヘスペリジンとその製造方法並びに用途 | |
US7713940B2 (en) | Water-soluble isoflavone composition, process for producing the same, and use thereof | |
JP2002199896A (ja) | 3”−α−モノグルコシルナリンジン含有組成物、その製造方法およびその利用方法 | |
JP4051482B2 (ja) | α−グリコシルヘスペリジンを含んでなる医薬組成物 | |
JPH04312597A (ja) | α−グリコシル フラボン類とその製造方法並びに用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018526605 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018799420 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018799420 Country of ref document: EP Effective date: 20181119 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18799420 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3052025 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20207001761 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020001069 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112020001069 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200117 |